Review Article

Insights into the Promising Prospect of G Protein and GPCR-Mediated Signaling in Neuropathophysiology and Its Therapeutic Regulation

Md. Mominur Rahman,1 Md. Rezaul Islam,1 Sadia Afsana Mim,1 Nasrin Sultana,1 Dinesh Kumar Chellappan,2 Kamal Dua,3 Mohammad Amjad Kamal,4,5,6 Rohit Sharma,7 and Talha Bin Emran8

1Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, Dhaka 1207, Bangladesh
2Department of Life Sciences, School of Pharmacy, International Medical University, Bukit Jalil, 57000 Kuala Lumpur, Malaysia
3Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, NSW 2007, Australia
4Institutes for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041 Sichuan, China
5King Fahd Medical Research Center, King Abdulaziz University, Saudi Arabia
6Enzymoics, Novel Global Community Educational Foundation, Australia
7Department of Rasa Shastra and Bhaishajya Kalpana, Faculty of Ayurveda, Institute of Medical Sciences, Banaras Hindu University, Varanasi, 221005 Uttar Pradesh, India
8Department of Pharmacy, BGC Trust University Bangladesh, Chittagong 4381, Bangladesh

Correspondence should be addressed to Md. Mominur Rahman; mominur.ph@gmail.com, Rohit Sharma; dhanvantari86@gmail.com, and Talha Bin Emran; talhabmb@gmail.com

Received 23 June 2022; Accepted 23 August 2022; Published 21 September 2022

Academic Editor: Alin Ciobica

Copyright © 2022 Md. Mominur Rahman et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

G protein-coupled receptors (GPCRs) are intricately involved in the conversion of extracellular feedback to intracellular responses. These specialized receptors possess a crucial role in neurological and psychiatric disorders. Most nonsensory GPCRs are active in almost 90% of complex brain functions. At the time of receptor phosphorylation, a GPCR pathway is essentially activated through a G protein signaling mechanism via a G protein-coupled receptor kinase (GRK). Dopamine, an important neurotransmitter, is primarily involved in the pathophysiology of several CNS disorders; for instance, bipolar disorder, schizophrenia, Parkinson’s disease, and ADHD. Since dopamine, acetylcholine, and glutamate are potent neuropharmacological targets, dopamine itself has potential therapeutic effects in several CNS disorders. GPCRs essentially regulate brain functions by modulating downstream signaling pathways. GPR6, GPR52, and GPR8 are termed orphan GPCRs because they colocalize with dopamine D1 and D2 receptors in neurons of the basal ganglia, either alone or with both receptors. Among the orphan GPCRs, the GPR52 is recognized for being an effective psychiatric receptor. Various antipsychotics like aripiprazole and quetiapine mainly target GPCRs to exert their actions. One of the most important parts of signal transduction is the regulation of G protein signaling (RGS). These substances inhibit the activation of the G protein that initiates GPCR signaling. Developing a combination of RGS inhibitors with GPCR agonists may prove to have promising therapeutic potential. Indeed, several recent studies have suggested that GPCRs represent potentially valuable therapeutic targets for various psychiatric disorders. Molecular biology and genetically modified animal model studies recommend that these enriched GPCRs may also act as potential therapeutic psychoreceptors. Neurotransmitter and neuropeptide GPCR malfunction in the frontal cortex and limbic-related regions, including the hippocampus, hypothalamus, and brainstem, is likely responsible for the complex clinical picture that includes cognitive, perceptual, emotional, and motor symptoms. G protein and GPCR-mediated signaling play a critical role in developing new treatment options for mental health issues, and this study is aimed at offering a thorough picture of that involvement. For patients who are resistant to current therapies, the development of new drugs that target GPCR signaling cascades remains an interesting possibility. These discoveries might serve as a fresh foundation for the creation of creative methods for pharmacologically useful modulation of GPCR function.
1. Introduction

Several genetic alterations and mutations have been recognized as hazardous factors in the pathogenesis of mental illnesses, like schizophrenia, bipolar disorder, and depression. However, although there have been substantial advancements in strategies to aid develop potent drugs as therapeutics for psychiatric disorders, currently, there is a gap in bridging treatment modalities with disease progression. This provides a continuing impetus to develop effective treatment options for such health conditions [1]. In the face of multiple complex genetic and environmental risk factor challenges faced when designing a targeted novel treatment for such pathological conditions, multiaacting receptor-targeted antipsychotics (MARTA) have been considered as antipsychiatric drugs [2, 3, 4]. Two kinds of receptors that have different synaptic transmission modalities are how neurotransmitters carry out their tasks. Fast synaptic transmission is induced by ligand-gated ion channels, which are made up of ionotropic receptors. Contrarily, metabotropic receptors are made up of GPCRs that bind to neurotransmitters and activate intracellular signaling pathways to reduce synaptic transmission and induce the gene expression required for antipsychotic effects [5, 6]. Notably, it is recognized that the majority of neuropharmacological medications control GPCR activity in the central nervous system (CNS) [7, 8, 9].

G protein-coupled receptors are 7-transmembrane domain proteins that form a multiprotein complex with members of an intracellular family of heterotrimeric G proteins comprised of a Ga subunit and a βγ dimer (Figure 1). There are several members of the Ga family that couple to different cohorts of effectors in the cell. GPCRs are the largest transmembrane proteins in the human genome. Half of such GPCRs possess sensory function, whereas the remaining half possess nonsensory function [10]. The nonsensory GPCRs regulate communications between various cells following activation via ligands like amino acids, peptides, amides, and lipid-derived products. Indeed, a vast majority of the currently available drugs work through GPCRs. In addition, GPCRs regulate a wide range of physiological functions, including chemosensory identification, endocrine regulation, and behavioral events [11].

Almost 90% of the nonsensory GPCRs exert their roles in both normal and complex brain functions and in regulating CNS physiology [12]. In this light, GPCRs have formed a primary target for antipsychotics like aripiprazole, olanzapine, and quetiapine. Some 367 receptors have been reported to contribute towards the nonsensory GPCRs [13]. Additionally, classical GPCRs, namely, dopamine, acetylcholine, and glutamate, have long been neuropharmacological targets in neurologie/neuropsychiatric drug development. As a consequence, such protein binding sites can be considered to mediate potential therapeutic effects in CNS disorders [14], and supporting this, a substantial proportion of current medications that are related to neuropharmacology act via GPCR-pathways within the central nervous system [15]. GPCR pathways are activated when they receive signals from the G protein. Receptor phosphorylation through G protein-coupled receptor kinases (GRKs) provides the main impetus for this type of signaling pathway [16, 17]. Antipsychotic drugs, mediated through dopamine receptors, are widely employed in CNS disorders, and the dopaminergic system is additionally important and provides a drug target in bipolar disorder, schizophrenia, Parkinson’s disease (PD), and ADHD [18, 19, 20]. Dopamine essentially acts on GPCRs with the potential ability to activate the G protein through either the Gi, Gs, or Gq pathways [21]. Mitochondrial complexes [22] and altered gene expressions [23] have been reported in such signaling cascades. Oxidative stress is a common feature too, due to the oxidative metabolism of dopamine [24], which may additionally induce glutathione [25].

Furthermore, glutathione’s precursor N-acetyl-cysteine is a potent antioxidant and has, likewise, been extensively investigated in psychiatric disorders [26–28]. Mental health diseases have yet to benefit from the present molecular medicine revolution, which has had an immediate influence on other areas of medicine. Research into the genesis and pathophysiology of complicated mental diseases is hampered by more than simply the CNS’s intrinsic complexity. These include an absence of a clearly defined pathology, limited access to tissues, and the humbling realization that behavior is more complicated than the sum of its parts [29]. Appropriate diagnosis is one of the most challenging issues in the development of a novel treatment approach when it comes to psychiatric disorders with limited understanding of their mechanism impacting cognition, behavior, and emotion. In this regard, an altered psychological function is strongly linked to psychiatric conditions. Consequently, GPCRs have been widely reported to possess huge potential with respect to potentially developing novel drugs or treatment approaches for psychiatric disorders [8, 30].

Therefore, this review is additionally aimed at investigating the pharmacokinetics, pharmacodynamics, and the significance GPCRs for developing novel treatment strategies for psychiatric disorders. The involvement of G protein-coupled receptors (GPCRs) in the development and treatment of serious mental diseases has nevertheless made significant progress in our knowledge. In this position essay, we analyze and integrate the knowledge that is presently available and discusses how it might be used to generate better drugs strategically. Due to space constraints, this review’s analysis has been limited to the most important mental illnesses and the most important GPCR families that have been implicated. Wherever possible, we have used reviews in place of source materials.

2. GPCRs in Central Nervous System

Humans and mice each contain 367 nonodorant GPCR superfamily members, with 343 common receptors, based on thorough analysis of public databases for mouse and human genome sequences, according to the study. There are 83 mouse and 26 human GPCRs that have not yet been discovered. Unexpected levels of orthology are found when GPCRs from the two species are directly compared. The survival of these molecules over time disproves functional redundancy among closely comparable receptors [31]. Nonodrant GPCRs are highly expressed in the central nervous
system, notably in the brain, with orphan receptors accounting for one-fourth of those found [32]. Nonodorant GPCRs make up around 80% of the 353 nonodorant GPCRs that are expressed in the mouse CNS. It has been shown by Komatsu that the CNS expresses considerable and selective levels of mRNA for six clusters of GPCRs, which collectively account for approximately 40% of the 322 nonodorant GPCRs discovered in mice. These six clusters are rich in neuropharmacological targets like dopamine, serotonin, acetylcholine, and glutamate which all have receptors for these chemicals in these clusters. The nonodorant GPCRs that are peculiar to the brain have a lot of potential as CNS medication targets, according to these findings [33].

3. GPCRs and Mood Disorders

3.1. Noradrenergic Receptors and Mood Disturbances with G Protein-Coupled Receptors. The distinctive primary synaptic components responsible for influencing emotional problems include the noradrenergic framework. After investigating the structure of peripheral blood cells, several critical assessments can be made with regard to the role of noradrenergic receptors in emotional disorders.

3.1.1. Studies on Peripheral Blood Cells

(1) Alpha2-Adrenergic Receptors. Several studies have reported alterations in blood platelets and alpha2-adrenergic receptor (alpha2-AR) mechanisms in subjects with mood disorders. In addition, it has also been observed that there were minimal changes in the receptor numbers in studies conducted with yohimbine-alkaloid radio ligands; one of the first radioligands developed to allow selective labeling of alpha2-ARs. Studies conducted with partial or complete agonists demonstrated wide variations in their activities, especially in weaker patients [34]. However, these findings highlighted several uncertainties, as the ligands involved here were bound to noradrenergic imidazoline receptors that were present on platelets [35, 36, 37]. Considering these findings, the sensitivity of alpha2 receptors seems inconclusive. This subject has also revealed the intricacies of assessments involving the bipolar issue. In addition, it was observed that the thickness of the alpha2-AR was enhanced in the platelets patients’ who had bipolar disorder [38].

(2) Beta2-Adrenergic Receptors. Studies on the quantities of beta2-adrenergic receptors in peripheral cells, however, have shown inconsistent outcomes, with one finding being that depressed individuals’ leukocytes have lower levels of beta-AR-stimulated AC activity [39, 40, 41, 42]. It has been postulated that this could be due to dysfunction of the receptor/Gs/AC complex. To date, it remains unclear which abnormalities in peripheral cells are identified with the pathophysiology of mood disorders and are associated with nonspecific stress or homeostatic mechanisms through both alpha2 and beta2 observations [43–45].

3.1.2. Impacts of Antidepressants and Mood Stabilizers

(1) Alpha-Adrenergic Receptors. Antidepressants have been demonstrated to lower alpha2-ARs in animal tissues, whereas alpha1-ARs have been shown to be increased [46]. Interestingly, prolonged lithium treatment has been found to reduce alpha2-AR-mediated behavioral consequences [47].

(2) Beta-Adrenergic Receptors. The majority of studies have discovered a predictable pattern of beta-AR downregulation in response to long-term antidepressant or electroconvulsive therapy treatment (ECT) [48, 49, 50, 51]. In the brain, long-term use of desipramine has been linked to an uncoupling of beta-AR and Gs [52, 51]. Receptor downregulation and receptor-G protein uncoupling both have been reported.
responsible for reduced downstream of cAMP signaling [53]. Moreover, desipramine prevents the dissolution of the beta-AR high-affinity complex, which prevents adenylyl cyclase from being activated downstream [54]. Lithium has been the subject of critical inquiries focusing on the results of evacuation stabilizers. There have been several studies assessing the effect of lithium on the actual adrenergic receptor in rodent cerebrums. However, an obstacle to beta-AR was that cAMP [55] was destroyed. Moreover, lithium does not avoid stimulant-instigated beta-AR downregulation [56].

3.1.3. Receptor Polymorphisms. Whereas there have been no reported associations between alpha2-AR polymorphisms and suicide or depression [57, 58], one study identified a non-significant link between a beta1-AR polymorphism, G1165C, and an increased antidepressant efficacy rate in depressed patients [59]. In recent research, the outcomes of yohimbine infusion on people with an alpha2C-adrenoreceptor subtype an-frame deletion (alpha2CDe322-325) [60] was studied. There was more whole-body noradrenaline spillover in homozygotes for the alpha2CDe322-325 polymorphism while they were at rest than in heterozygous individuals. In homozygotes, the effects of yohimbine were more pronounced and persisted longer than in the other groups. Because catecholaminergic responses have a similar impact on mood disorders, this receptor polymorphism is being studied more thoroughly in this area.

3.2. Serotonergic Receptors Coupled with G Protein and Mood Disturbances. The efficacy of serotonergic-mediated medications in the management of depression has been a driving force behind the idea that serotonin plays a crucial role in sadness and mood disorders. In this regard, the “serotonin hypothesis” of clinical depression is now over 50 years old and, in a nutshell, proposes that reduced serotonin-mediated signaling has a pivotal role in the pathophysiology that culminates in depression. This view is based on the adverse depressive actions of amine depleting drugs exemplified by reserpine, the antidepressant properties of tricyclic antidepressant and monoamine oxidase inhibitor drugs that augment serotonin and other monoamines within the synapse, and extensive studies showing aberrant serotonergic signaling in patients with sadness and mood disorders. Parallel information for the bipolar disorder is less extensive but is growing. Further evidence that serotonin plays a role in such situations comes from the discovery of receptor polymorphisms linked to illness susceptibility and treatment response in specific regions of the brain.

3.2.1. Impacts of Antidepressants and Mood Stabilizers

(1) Receptors of 5HT1A. During long-term antidepressant therapy, serotonin transmission increases in the hippocampus, leading to desensitization of dorsal raphe somatodendritic 5HT1A autoreceptors and support for 5HT1A receptor function in mood disorders [61]. In patients with bipolar disorder, 5HT1A receptor impairments can be mitigated by a stable lithium treatment [62]. A consistent energizer therapy has also been established to enhance the uncoupling of the 5HT1A receptor-G protein [63].

(2) Receptors of 5HT2. Antidepressants have been shown to decrease the cortex-authoritative 5HT2A receptor functions [64]. The evidence for the part of the 5HT2A receptor in the disposal stabilizer operation instrument is significantly less clear. Blended results have been provided by exploring the 5HT2A receptors after a consistent lithium association. Lithium induces a typical activity within the cutoff retention of the 5HT2 receptor with the most grounded hippocampal confirmation [62] at the same time when platelets were affected in bipolar sufferers, thereby, limiting the upward thrust of lithium inside the 5HT2A receptors [65].

3.2.2. Polymorphisms of Receptors

(1) Receptors for 5HT1A and 5HT1B. Terock et al. and Han et al. [65, 66] have reported that the C-1019G 5HT1A polymorphism is related to a significant self-destruction of the 5HT1A agonist stimulant response to flibanserin. A relationship between the stimulant response and both this polymorphism [67, 68] and Gly272Asp [68] has been revealed in a number of studies. Albert et al. [69] found that the hereditary impact of the 5HT1A receptor-encoding quality of HTR1A and the serotonin carrier encoding quality of SLC6A4 impacts the clinical results of patients treated with citalopram. It has been reported that the G861C locus of the 5HT1B quality is implicated with distress, yet not with bipolar disorder [70]; albeit, no such association was found in other investigations [66].

3.3. Dopaminergic Receptors with G Protein-Coupled and Mood Disorders. Dopamine has long been a focus of schizophrenia-related research, but its role in mood disorders has gotten far less attention. Despite this, mounting data suggests that dopamine plays an important role in a wide range of illnesses. Goal-directed behavior is influenced by the dopamine systems in the midbrain and mesolimbic systems, which are linked to motor activity, motivation, and reward pathways respectively. All of these functions can be substantially damaged in states of depression and mania. Pharmacological therapies for mood disorders have been demonstrated to ameliorate mood symptoms, showing that G protein-coupled dopamine receptors play an important role in the development of mood disorders.

3.3.1. Polymorphisms of Receptors

(1) Receptor D1. Whereas various investigations have failed to see any bipolar changes in the D1 receptor gene [71, 72], a connection between polymorphism of the D1 receptor A48G and bipolar disease has been observed [73, 74].

(2) Receptor D2. Different research has sought to find a link between polymorphism of the D2 receptor and bipolar illness; however, such a link has not been discovered. Nevertheless, two evaluations have reported cautious, but optimistic outcomes. Overs et al. [75] investigated and reported a critical connection between the D2 receptor and bipolar
disorder in an European multicenter examination. Han chinese patients with a bipolar exacerbation was not underlined when attempted in Caucasians. Kulmala et al. [76] saw a relationship with a D2 receptor polymorphism recommending a potential race-express threat issue.

3.4. Cholinergic Receptors with G Protein-Coupled and Mood Disturbance. There has long been speculation about the role of the cholinergic framework in bipolar disorder. This was based on experiments showing that cholinergic agonists and antagonists have significant mood and behavioral effects. Most of the examinations detailing openness to cholinergic receptors in disposition issues have been exceptionally backhanded. For instance, REM occurs during particular patterns of sleep, yet its initiation might be set off by cholinergic actions as observed in healthy volunteers. The induction of REM sleep in persons with mood disorders who are not taking medication is more rapid with the administration of arecoline (a cholinergic agonist) (primarily focused on bipolar disorder) [62]. Several antidepressants possess anti-cholinergic effects, including tricyclic and serotonin reuptake inhibitors, and hence, their useful biological actions can sometimes be adversely affected by sedation, psychomotor and memory impairment, a dry mouth, and blurred vision. Several studies have provided contradicting reports on the impact of lithium on function of the muscarinic receptor. It has been reported [77] that lithium obstructs the super sensitivity of the muscarinic receptor despite influencing the quantity of receptor within restricted areas, suggesting that it works at a postreceptor site [78, 79].

3.5. GABAergic Receptors and Mood Disturbances That Are G Protein Coupled. G protein-coupled GABA-B receptors have been demonstrated to be beneficial in the treatment of mood disorders in a modest number of trials. GABA-B agonist baclofen has been demonstrated to cause depression in a tiny percentage of individuals; therefore, discontinuing the medication can help alleviate depression [80]. Lithium, valproic acid, and carbamazepine, among other mood stabilizers, increase GABA-B receptors in the hippocampus when taken on a long-term basis [81, 82].

3.6. Glutamatergic Receptors Coupled with G Protein and Mood Disorders. Most neurotransmitter systems are thought to have a threshold for excitation that is regulated by the glutamatergic system, which is the principal excitatory neurotransmitter of the CNS. Recently, research has focused on the possible significance of mood disorders in a possible link between the two. According to current investigations, the glutamatergic system appears to be important in the development and treatment of mental health issues [83–85]. Currently, investigations are jointly evaluating both NMDA [85] and AMPA [65] ionotropic receptors in the treatment of mood disorders. These will not be detailed as our focus is GPCRs; however, there are recent reviews that include a comprehensive discussion of the glutamatergic system’s function in mood disorders [83–85].

3.7. Receptors of G Protein-Coupled Neuropeptides and Mood Disorders. As a neurotransmitter, neuropeptides are a group of short-chain amino acids. One of the initial interests in biological psychiatry was the role of modified endocrine function in mood disorders [86].

3.7.1. Receptors of Corticotrophin-Releasing Factor (CRF). Because of its growing importance in neurological illnesses and the numerous unanswered questions it has raised in people and animal models, CRF has become one of the most intensively studied neuropeptides [62, 87, 88]. Anxiolytic and overactivity effects have been demonstrated in preclinical studies employing direct models for antagonists of CRF receptors, in particular for subtype CRF receptor-1 [89]. These findings led to the open trial of R121919, a CRF receptor-1 antagonist, in 24 individuals with depression [90]. Initial results have been promising, and further clinical trial results are awaited. At least two genetic linkage and association studies, however, have found no evidence linking CRF polymorphisms to bipolar disorder [91–93].

4. Schizophrenia and GPCRs

4.1. Dopaminergic Receptors Coupled to G Protein and Schizophrenia. Despite the fact that the underlying pathogenesis of schizophrenia is clearly highly complex, the dopamine hypothesis and its various revisions provide a valuable and scientifically based explanation for the disease’s psychotic symptoms (particularly hallucinations and delusions). Dopamine dysregulation in emotional processing areas like the amygdala and hyperactivity of dopamine transmission in the mesolimbic areas are hypothesized to be associated with schizophrenia, as is the hypoactivity of dopamine transmission in the prefrontal cortex.

4.1.1. Impacts of Antipsychotic Medications. To begin with, the idea of overactive dopamine was put up due to research showing that conventional antipsychotics have a high D2 affinity and that receptor affinity has a direct correlation to the clinical response [94]. Antipsychotic effectiveness appears to be best around 65% to 70% D2 receptor occupancy, while higher than 80% occupancy greatly raises the incidence of extrapyramidal symptoms (EPS), a well-known adverse effect. PET and SPECT investigations have supported this connection. However, several studies have shown that D2 receptor binding alone is not adequate to explain schizophrenia’s physiology. In the first place, despite 70 percent or more receptor occupancy, standard antipsychotics are not helpful for all...
people with schizophrenia [3]. Second, traditional antipsychotics are only successful in treating about 70% of positive symptoms [4] and have been reported ineffective in treating negative and cognitive symptoms [95].

4.1.2. Receptor Polymorphisms. In the light of the pivotal role of D2 receptors in the pharmacological action of antipsychotics, numerous investigators have looked into the role of D2 receptor polymorphisms in schizophrenia. Several studies, that have included different groups of independent investigators undertaking metaexaminations, have reported a positive relationship between polymorphisms and schizophrenia related to the D2 receptor Ser311Cys [96–99]. Nonetheless, other evaluations have found no connections [99]. A relationship between Ser311Cys and adverse effects was found in one of the investigations [100]. Furthermore, a few further studies have revealed that schizophrenia is linked to a second polymorphism in the D2 receptor, which highlight a specific region, -141C Ins/Del [101, 102]. Various assessments have additionally described assorted other polymorphisms of the D2 receptor, for instance, C957T [103], His313 [104], and Taq1A locus [105]. Several studies have linked the -141C Ins/Del allele to the time or degree of response to antipsychotic drugs, with the -141C Ins allele being associated with a better response; however, other studies have contradicted these findings [60, 104, 106, 107]. The association between treatment effects and the Taq1A locus [108], Ser311Cys polymorphism [68], and His452Tyr polymorphism [107] has been evaluated in a number of studies. The D3 receptor polymorphism, Ser9Gly, is the most frequently analyzed in relation to the D3 receptor, regardless of a lack of schizophrenic symptoms associated with it [109, 110]. The connection between this polymorphism and the response to antipsychotics has been reported in a few studies [111, 112]. There is some distinction from these examinations concerning which subset of indications principally is connected with this polymorphism [113]. The Gly9 allele is reported to be associated with the response to atypical antipsychotics [104]. G-712C [114], G-7685C [111], and G-712C [114] are other D3 receptor variations that have demonstrated a potential relationship with schizophrenia that some consider to be relatively nominal. Indeed, studies are yet to demonstrate a truly extensive association with schizophrenia [115, 116]. Other studies still have evaluated the relationship between polymorphism and the response to the atypical antipsychotic clozapine [24] which was observed, but not in all studies [117, 118].

4.2. Serotonergic Receptors Coupled to G Protein and Schizophrenia. Although there is contradictory evidence that serotonin receptors are changed in schizophrenia, pharmacological results of the serotonergic action of propyphenytoxic drugs of abuse and atypical antipsychotic medications show that serotonin plays a crucial role in such illness. The strongest evidence for serotonin’s significance in schizophrenia has come from pharmacological studies. D-Lysergic acid diethylamide (LSD) can elicit psychotic symptoms in healthy people because of its structural similarity to serotonin, prompting further inquiry into this neurotransmitter system in psychosis. LSD affects the raphe nucleus’ serotonin system via 5HT1A receptors, and hallucinations are almost certainly induced by the agonist activity of the 5HT2A receptor [119]. The last two decades of research described at least fifteen 5-HT receptor subtypes based on the specific biochemical signaling pathways, as presented in Table 1.

4.3. Glutamatergic Receptors Coupled to G Protein and Schizophrenia. A great deal of evidence suggests that the glutamatergic system is involved in schizophrenia. The majority of the existing evidence, as with mood disorders, is focused on the role of ionotropic glutamatergic receptors. There are several reviews that cover this topic [121, 122]. Support of a glutamate role in schizophrenia is centered largely on pharmacological investigations. Studies have shown that phencyclidine (PCP) and amphetamine-instigated schizophrenia-like social symptoms are potentiated by group-I enemies of metabotropic glutamate receptors (mGlur1 and mGlur5) [123]. Get-together, group-I agonists limit sensorimotor gating impairments mediated by amphetamine and PCP-induced dopamine discharge in rodents in the prefrontal cortex [124]. Agonists of the get-together II receptor (mGlurR2/3) block direct incitement achieved by PCP and working memory impairment [125, 126]. In sensorimotor gating, which aggrivated schizophrenia, knockout mice mGluR1 and mGluR5 exhibit exacerbation [123].

5. GPCRS in Depression

5.1. Depression and Antidepressant Activity G Protein Subunits. The majority of the current antidepressant medications interact with G protein-coupled receptors (GPCRs). For example, 5-HT1A receptor acting partial agonists buspirone or aripiprazole mediates their effects through a variety of monoaminergic GPCRs, thereby affecting endogenous synapse levels. They produce serotonin reuptake inhibitors (SSRIs) like fluoxetine and monoamine oxidase inhibitors (MAOIs) like selegiline, as well as serotonin reuptake inhibitors (SSRIs). Members of an intracellular family of heterotrimeric G proteins, consisting of a Ga subunit and a βγ dimer, form a multiprotein complex with seven transmembrane domains with G protein-linked receptors [54].

5.1.1. Levels of G Protein Expression. Antidepressant drug therapy does not appear to alter G protein expression levels in the central nervous system (CNS) consistently in preclinical trials. Chronic treatment with the tricyclic antidepressant imipramine results in relatively stable mRNA expression of Gas, Gao, and Gai in the rat hippocampus, according to one study [127]. However, the measurement of G protein mRNA levels does not necessarily provide insight into its protein expression [128]. As a result, the amount of G protein present is not always accurately reflected in these observations. In studies focused on protein level measurements, those of Gas, Gao, and Gai in the rat cerebral cortex were unaffected by chronic treatment with amitriptyline, a dual serotonin-norepinephrine reuptake
inhibitor (SNRI), or by desipramine, tranylcypromine, or electroconvulsive shock [54, 129].

5.1.2. Impact on Gas Localization and Signaling. Notwithstanding the absence of any immediate consequence on G protein verbalization levels, treatment with solutions of energizers (checking for amitriptyline, desipramine, and iprindole) brings cAMP focuses up in the brain of rodents, not in the liver or kidney, in a GAPS-subordinate manner [130–132]. Notwithstanding energizer arrangement items, constant electroconvulsive treatment reinforces the coupling among GHAs and adenyl cyclase. Also, extended cAMP-subordinate kinase movement (for example, protein kinase A) was seen in the rodent cerebrum after predictable upper treatment, reliable with this all-encompassing creation of adenylyl cyclase [133]. When desmethyli mipramine was led constructively, but not brutally, these modifications in the cerebral cortex were not observed in the hippocampus, striatum, or cerebellum [134].

6. G Protein Signaling Regulators as a Potential Drug Target for the Central Nervous System (CNS)

G protein-coupled receptors (GPCRs) are colossal focuses for medication exposure. In the transduction of GPCR signals, the G protein signaling- (RGS-) protein family controller has a primary breaking point. GPCRs are common pharmacological targets. RGS proteins quicken the deactivation of G proteins. Likewise, they produce communication signals to diminish GPCR motioning by inducing the speed of GTP hydrolysis by the G protein α-subunit, which prompts Ga–Gβγ reassociation. Blocking the binding of the G protein to Ga*GTP, for the current condition, would induce a delayed lifetime of the Ga subunit in the GTP-bound state, improving the receptor-engaged reaction through elevated levels of free Ga*GTP and Gβγ subunits. (b) RGS proteins as Ga effectors: RGS proteins, in a similar way, have a positive operation in GPCR motioning as a result of p115-RhoGEF and the related proteins PDZ-RhoGEF and LARG. On binding, G13α, the GEF action of p115-RhoGEF broadened, affecting RhoA incitation, accomplishes the downstream impacts of cytoskeletal changes and transcriptional control. P115-RhoGEF additionally deactivates G13α by procedures for RGS-box GAP improvement, at any rate not before the signal is transmitted forwards. For the current situation, inhibiting the GRS-box–Ga interactions by small particle mediation should decrease G13α-subordinate RhoA beginning. LARG stands for leukemia-associated RhoGEF;

**Table 1: The family of 5-HT receptors [120].**

| Receptor | Selective agonists | Potential | Type | G protein effector | Mechanism of action | CNS distribution |
|----------|--------------------|-----------|------|-------------------|---------------------|------------------|
| 5-HT1 (5-HT1A, 1B, 1D–F) | DOI^4, BW 723C86, Ro 600175 | Inhibitory | Gi/G0-protein coupled | Gi/o | Decrease in intracellular cAMP levels and inhibition of AC | Cerebral and frontal cortex, hippocampus |
| 5-HT2 (5-HT2A–C) | DOI^4, BW 723C86, Ro 600175 | Excitatory | Gq11-protein coupled | Gq/11 | Activation of PLC, enhancing in IP3 and DAG intracellular concentration, and rise in intracellular calcium | Nucleus accumbens, basal ganglia, cerebellum |
| 5-HT3 (5-HT3A, 3B) | DOI^4, BW 723C86, Ro 600175 | Excitatory | Ligand-gated Na+/K+ channel | — | Depolarization of cell plasma membrane | Hippocampus, amygdala, nucleus accumbens |
| 5-HT4 (5-HT4A–H) | DOI^4, BW 723C86, Ro 600175 | Excitatory | Gs-protein coupled | Gs | Increased intracellular cAMP concentration and activation of AC | Hippocampal membranes |
| 5-HT5 (5-HT5A) | — | Inhibitory | Gi/G0-protein coupled | Gi/o | Decrease in intracellular cAMP levels and inhibition of AC | Olfactory bulb, neocortex, hippocampus |

---

*Oxidative Medicine and Cellular Longevity*
Pi stands for phosphate group; RGS stands for the regulator of G protein signaling [135].

6.2. Role of Endogenous RGS Protein. The dormant synaptic potential formed when heterotrimeric G proteins change molecule channels are signaled by metabotropic G protein-coupled receptors. Numerous neurons create excitatory postsynaptic possibilities interceded by G proteins of the Gaq/11 family, thus enacting phospholipase C-β. GTPase-activating proteins (GAPs) are believed to quicken GTP hydrolysis and quickly turn off G proteins. However, the contribution of GAPs in neuronal Gaq/11 flagging has not been analyzed. It has been shown that controllers of G protein flagging (RGS) proteins provide a vital GAP movement at neuronal Gaq/11 subunits. Obstruction of neighborhood 2-pore region potassium coordinates in cerebellar granule neurons was reconstituted by conveying fanciful Ga subunits that are activated by Gαi/o-coupled receptors, in this way bypassing endogenous Gaq/11 subunits [136, 137].

6.3. Specificity of RGS Protein. RGS proteins are common negative G protein signaling regulators that work by speeding up the rate of GTP hydrolysis on G protein α subunits [138]. The large number of signaling pathways involving RGS and G proteins raises the question of how specificity in mutual recognition is achieved. In examinations using scrubbed proteins or proteins conveyed in cell culture [135, 139, 140], progression towards this way is made by portraying the instances of unique RGS-G protein associations. To fully comprehend the specificity of RGS protein function within a given G protein cascade, however, this knowledge is insufficient on its own. RGS proteins may also be needed to distinguish between the free activated G protein α subunits and their complexes with effectors or other regulatory proteins in order to make sure that the timing of the full signaling event delivered by a certain route is physiologically acceptable [141].

6.4. RGS Proteins as Drug Targets. Numerous neurological diseases are linked to RGS proteins. The development of RGS-insensitive Ga subunits and RGS-insensitive knock-in mice has greatly contributed to our knowledge of the role RGS proteins play in these disorders [142]. These mutant Ga subunits cause an uncoupled RGS-Gα state, which is critical to understanding the implications of disrupting this interaction on the body’s physiological functions. RGS proteins play a critical role in signal transduction, as demonstrated by subsequent RGS deletion or knockdown studies that replicate an environment in which GPCR signaling is not restrained by RGS proteins [143–145].

6.5. RGS Inhibitors as Clinical Therapeutic Agents. RGS proteins, which offer an alternate approach of controlling the activity of G protein-coupled receptors, the target of many medications, have recently come to light as possible therapeutic targets. RGS protein inhibitors must be able to cross the blood-brain barrier, be permeable to cells, and disrupt protein-protein interactions (RGS-Gα), depending on the therapeutic target [135].

7. GPCRs in CNS

Extensive examinations of the genome sequence databases of humans and mice have revealed that the nonodorant GPCR superfamily consists of 392 receptors in mice and 367 receptors in humans, with 343 receptors being mutually expressed between these two species. Within the CNS, nonodorant GPCRs are abundantly expressed, with 6 clusters being noted [17, 146].

7.1. Medium-Sized Spiny Neurons (MSNs) Control Psychiatric Symptoms in the Striatum. The striatum is the basal ganglia’s main input structure, and dopamine primarily regulates how information is processed there [147]. The nigra pars compacta (SNc) and the ventral tegmental area (VTA), containing nuclei associated with reward processing, reinforcement learning, and motor control, both innervate the striatum, with dysfunction in the VTA, in particular, being associated with schizophrenia. Within the striatum, MSNs, which represent a specialized type of GABAergic inhibitory cells, represent some 95% of neurons [148, 149]. MSNs have striatonigral and striatopallidal pathways and, based on their projection, can be classified into two types of neuronal populations. The striatonigral (direct) pathways project onto the medial globus pallidus (MGP) and the SNr (substantia nigra pars reticulata) and express dopamine D1 receptors and neuropeptide substance P. Adenosine A2A receptors, neuropeptide encephalin, and dopamine D2 receptors can be found in the striatopallidal (indirect) pathways, which project onto the lateral globus pallidus (LGP) [150, 151]. In the light of the known involvement of MSNs in the development of schizophrenia and PD [147], their differential functions require elucidation.

7.2. Antipsychotics Exerts Therapeutic Action through Dopamine D2 and D1 Receptors. Dopamine D2 and G-coupled dopamine D1 receptors are both strongly expressed in the striatum, which is where the majority of routinely prescribed antipsychotics are taken [147]. Schizophrenia has complex inheritance patterns and includes cognitive deficits and positive and negative symptoms [152]. These schizophrenic symptoms indicate a hyperactive dopaminergic transmission (mesolimbic pathway) as well as a lessened dopamine release in the prefrontal cortex [153]. Aripiprazole is a partial dopamine D2 receptor agonist and is classified as an atypical antipsychotic. In a situation of excessive dopaminergic neurotransmission, it also functions as a D2 receptor antagonist [154]. In schizophrenia, D2 signaling is considerably hyperactive [155], and in the prefrontal cortex, the D1 receptor is decreased [156].

7.3. Striatal-Enriched GPCRs Are a Potential Drug Target for Psychiatric Disorders. The striatum is an important part of the brain that might be studied as a possible treatment target for mental disorders. GPR88, GPR52, and GPR6, as well as dopamine D1 and D2 receptors and adenosine A2a receptors, are the most highly expressed GPCRs in the mouse striatum, according to transcriptional analyses [17]. GPR88, GPR52, and GPR6 are orphan GPCRs, and their transcriptional expression patterns are almost indistinguishable from

Oxidative Medicine and Cellular Longevity
D2 and D1 receptors in the cerebrum. In both striatonigral, GPR88 is communicated, and striatopallidal neurons communicate D2 and D1 receptors, individually, as per in situ hybridization (ISH) investigation (basal ganglia), while GPR6 and GPR52 are communicated in the striatopallidal neurons (Figure 2). Within the taking after segment, these three vagrant GPCRs, as well as the A2a receptor, are briefly clarified.

7.3.1. Adenosine A2a Receptor. Adenosine regulates a wide range of brain activities by acting on adenosine A1 and A2a receptors. The A2a receptor is reported to have a major impact on a variety of neuropsychiatric functions, fundamentally through glutamatergic and dopaminergic neurotransmission, which may have potential value in a number of neurological disorders. Niemann-Pick disease, Autism spectrum disorders, and schizophrenia have been linked to A2A receptor agonists, whereas A2A receptor antagonists have been linked to Alzheimer’s disease, attention deficit hyperactivity disorder, fragile X syndrome, depression, and anxiety [9, 157]. The Gs-coupled A2a receptor is preferentially expressed in the striatopallidal MSNs (Figure 2) and is reported to play a key role in motor function regulation as its ligand can trigger characteristic motor effects [158].

In this light, GABAergic communication from striatopallidal MSNs guided by A2a receptor antagonists may provide a PD treatment strategy [159, 160]. As the A2a receptor can regulate dopaminergic neurotransmission, this may, hence, have psychopharmacological implications. A key component that is considered to allow A2a inhibitors to intervene in motor activity is by modulating GABA discharge.

Some researchers believe that future treatments for mental illness will be based on an inhibitory interaction between D2 and A2a receptors. Antipsychotic effects of psychostimulants can be altered by A2a agonists in animal models [161]. Pharmacological and hereditary investigations show that the movement of the A2a receptor impacts patients’ schizophrenia-like behavior. Caffeine, as a non-selective A1 and A2a receptor antagonist, has demonstrated both positive and negative effects in schizophrenia, depending on when it is administered, for how long and when its actions are evaluated [162]. Most schizophrenia symptoms primarily derive from perturbed dopaminergic and glutamatergic neurotransmission; however, alterations in the adenosinergic system also have been reported. As the adenosinergic system is associated with motivational and cognitive processes, the impact of adenosine on dopaminergic- and glutamatergic-mediated neurotransmission likely depends on the baseline status of these processes when the adenosinergic system is being manipulated. As noted, adenosine A1 and A2A receptor agonists reverse both NMDA receptor hypo- and dopaminergic hyperactivity. Whereas caffeine may worsen the positive symptoms of schizophrenia subjects (such as delusions and hallucination), a number of studies (but not all) have reported that it positively impacts learning and memory tasks [162]. However, cognitive performance can be affected by multiple potentially competing factors including attention and motivation as well as stress, and differential effects on these can well account for overall improvements in learning and memory under some conditions and worsening under others. Cellular investigations have demonstrated that adenosine A2A receptor activation decreases the affinity of dopamine D2 receptor agonist binding sites on striatal neurons, without altering the affinity of dopamine D2 receptor antagonist binding or the expression of D2 receptors. Extensive studies reviewed by Ferré and colleagues support the concept that GPCR oligomerization can readily occur and that GPCR homodimers represent both functional and structural building blocks whereby heteromers, comprising of two different homodimers, can be formed that are each able to signal via their chosen G protein. This appears to be particularly likely in relation to A2A receptor-D2 receptor heteromers and potentially accounts for their known allosteric mechanisms and multiple unique pharmacological and biochemical properties. On chromosome 22q12–13, a single nucleotide polymorphism (SNP) on the
A2a receptor provides a candidate schizophrenia susceptibility gene [163], which, again, ties the adenosine A2a receptor to various mental disorders that include schizophrenia, as well as depression and anxiety. As indicated by a variety of studies, the adenosine A2a receptor “fine tunes” glutamatergic and dopaminergic network balance [164]. In this regard and as noted, the opposing interaction of D2 and A2a receptors in the striatum, in relation to dopaminergic action, provides potential antipsychotic activities in schizophrenia, as an antagonist of the dopamine receptor [161]. In relation to glutamatergic action and as reviewed by Komatsu [165], both A2a and A1 receptor agonists have been reported to reduce the electroencephalogram (EEG) and behavioral effects of NMDA receptor inhibitors [166]. It has been shown that NMDA receptor activity may be influenced by both A1 and A2A receptor function in schizophrenia models of NMDA receptor hypofunction. While the NMDA antagonist effects in animal models of schizophrenia are reversed by the blockage of A2A receptors and the genetic deletion of the receptor, this suggests that correcting the imbalance in adenosine A2A receptors may rectify the hypofunction of NMDA antagonists [167].

7.3.2. GPR88. Human gene association studies show a rising correlation between GPR88 function and mental health issues, including schizophrenia and bipolar disorder as well as neurodevelopmental and neurodegenerative disease [168–170]. Following exposure to a variety of psychoactive substances, including antidepressants, mood stabilizers, and drugs of abuse, mRNA levels of Gpr88 have been observed to vary in animal models. Hence, in this light, GPR88 may provide a promising target in the development of new treatment strategies for neurological disorders. By deleting the Gpr88 gene in mice, striatal-dependent physiology, neural networks, and behaviors are affected, resulting in hyperactivity, stereotypies, and deficits in learning and motor coordination, as well as changes in reward-driven behaviors. The expression of GPR88 beyond the basal ganglia and its knockout suggest that GPR88 has potential influence on a broad range of behaviors and brain physiology; however, how this is specifically achieved from a molecular basis remains to be elucidated as, currently, selective pharmacological probes to manipulate GPR88 remain relatively few. Available structural studies suggest that GPR88 is an atypical GPCR. Although considered as part of the class A (rhodopsin-like) family of GPCRs, which is the largest group and accounts for approx. 80% of GPCRs (including hormones, neurotransmitters, and light receptors), GPR88 minimally shares amino acid sequence and functional similarities to other members of this class. So far as we know, the structure of the GPR88 transmembrane binding pocket is more in line with class C GPCRs (which include the metabotropic glutamate family, GABA receptors, calcium-sensing receptors, and taste receptors). Although significant efforts have been made to deorphanize GPR88 (i.e., discover ligands that are highly selective), several hurdles persist, and hence, the signaling pathway(s) and receptor capabilities of GPR88 remain mostly unknown. Studies including the electrophysiological evaluation of MSNs taken from knockout mice lowered tonic GABAergic inhibition and responses to synaptically generated GABA, whereas glutamatergic excitatory synaptic transmission was increased. This shows that GPR88 may play a role in glutamatergic transmission, together with the phosphorylation of the AMPA-type glutamate receptor GluR1 in GPR88 knockout mice. According to the findings, GPR88 appears to have a role in the response of GPR88 knockout mice to agonists of the muscarinic and opioid delta and mu receptors. GPR88 has been discovered as a genetic risk factor for bipolar illness and schizophrenia by genetic association analysis. GPR88 dimerization with nonorphan GPCRs is supported by recent findings [171–174] and demonstrates an ability of GPR88 to dampen the signaling of many GPCR receptors in close proximity as well as impede β-arrestin recruitment. As ligands for GPR88 are recently being described, including 2-PCCA, RT1-13951–33, and phenylglycinol derivatives, our understanding of the signaling pathways associated with GPR88 and its physiological roles will likely become clearer in the near future.

7.3.3. GPR6. GPR6 is mostly expressed in the basal ganglia’s striatopallidal neurons (Figure 2) [17]. GPR6 is an orphan receptor that has a ubiquitous function and generates an increase in intracellular cAMP levels when it is linked to a stimulatory Gs-protein. GPR6 was initially described as a lysophospholipid sphingosine 1-phosphate (SIP) receptor; however, this view has not been confirmed by others [175]. The corticostriatal circuitry and the dopaminergic system are considered engaged with human instrumental learning [176]. In rodent essential cerebellar granule neurons, overexpression of GPR6 augments neurite outgrowth [177]. Nishi and Shuto examined the neurochemical and behavioral phenotypes of GPR6 knockout mice to aid define the receptor’s function. GPR6 deletion mice demonstrated a decrease in striatal cAMP and an elevation in dopamine, as well as increased movement actions. A reduction in dyskinesia in a PD mouse model after therapy with apomorphine and quinpirole was also noted, implying that GPR6 inhibition may provide benefit PD. In GPR6 knockout animals, the phosphorylation of dopamine and the cAMP-regulated phosphoprotein of 32 kDa (DARPP-32) at Thr34 increased significantly, while the production of DARPP-32 in the striatum did not. The cAMP/PKA pathway phosphorylates DARPP-32 at Thr34, which is essential for the signal transduction of dopamine D2 and D1 receptors [178]. The D2 receptor antagonist haloperidol has been shown to increase DARPP-32 phosphorylation at Thr34 in striatopallidal neurons [178–180]. Increasing evidence supports the concept that GPR6 could potentially be targeted as a treatment strategy for schizophrenia.

7.3.4. GPR52. Despite the fact that the antipsychotic medicine reserpine is reported to be a surrogate ligand for actuating intracellular cAMP accumulating and receptor internalization, GPR52 is an orphan GPCR, indicating that it may be a Gs-coupled receptor [165]. Over 90% of the amino acid corrosive grouping property of GPR52 is conserved in vertebrates, and it is broadly distributed in the brain, notably the striatum, with no apparent alterations between species. Despite the fact that
GPR52 is expressed in the basal ganglia, it also communicates with a high number of D1-expressing neurons in the prefrontal cortex. This is an unusual expression profile (Figures 2 and 3). As a result of this, GPR52 activation may promote good effects of schizophrenia by antagonizing Gi/o-coupled D2 receptor action in striatopallidal MSNs, while also reducing schizophrenic adverse effects and cognitive disability by upgrading NMDA receptor movement in prefrontal cortical neurons via protein kinase A (PKA), as can be seen in D1 receptor-NMDA signal transduction [181, 182].

An extensive study of GPR52-expressing neurons’ axonal extensions shows that the limbic neural circuit, which is critical for memory and spatial memory, is communicated by GPR52. Dopaminergic neurons in the midbrain get a negative compensatory signal from GPR52-expressing neurons in the habenular nucleus [183]. Prefrontal cortex GPR52-expressing neurons are almost entirely glutamatergic, while only around 10% are GABAergic. The GFP-fused human GPR52 is useful in vitro in hGPR52-GFP transgenic (Tg) mice, and hGPR52-GFP and D2 receptor proteins are clearly separated across striatal regions. The GPR52-GFP is located largely in the LGP, while the bulk of D2 receptor proteins are detected in the striatum. LGP’s axon terminals contain GPR52, whereas the dendritic spines of striatal neurons are home to D2 [17]. Up until now, GPR52 transgenic (hGPR52) and GPR52 knockout (KO) mice seemed to be created, as well as examined. The methamphetamine-(MAP-) interceded hyperlocomotion of hGPR52 Tg mice is less articulated than non-Tg mice, despite how hGPR52 Tg mice have ordinary locomotor action under typical conditions. The disclosure of GPR52’s atomic component could prepare for a new examination for the dopamine and NMDA frameworks, just as the advancement of new antipsychotic drugs. Some GPCRs in the specific types of psychiatric disorders with the function, polymorphisms, and drugs targeting receptors are shown in Table 2.

Figure 3: A potential sign transduction pathway for GPR52.

8. Treatment of Psychiatric Disorders

8.1. Modes of Action of Antipsychotics in Psychiatric Disorders. Catecholamine neurotransmitters, such as dopamine, are found in the brain [186]. Parkinson’s disease, schizophrenia, obsessive-compulsive disorder, bipolar disorder, and hyperactivity-hyperactivity disorder are only a few of the CNS illnesses where dopamine plays a major role [187, 188]. D1 and D2 dopamine receptors are two subclasses of G protein-coupled receptors (GPCRs), which are responsible for the action of dopamine. When it comes to receptor subclasses, D2 has D2R, whereas D1 has the D1 receptor (D1R), while receptor subclasses D5 and D2 and subclasses D4 and D3 each have their specific receptor (D5R) [189]. The basal ganglia receive their information mostly from the striatum, which has the greatest number of D1R and D2R neurons [190]. In schizophrenia, the SNc and the VTA both have a substantial impact on striatum
innervation; it is considered that the VTA is hyperactive in positive symptoms [191]. The striatum includes 5% of inter-neurons including large aspiny cholinergic neurons and 95% gamma-amino butyric acid (GABAergic) medium-sized spiny neurons (MSNs) [151], composed of direct (striatoni-gral) and indirect (striatopallidal) pathways [192]. The striatoni-gral neurons transmit onto the MGP (medial globus pallidus) and SNr (substantia nigra pars reticulate) and prompt D1R and P, neuropeptide substances. The striatopal-lidal neurons project toward the globus pallidus (LPG) and contact the SNr/MGP. Moreover, it can express D2R, A2a adenosine receptor, neuropeptide encephalin, and two orphans GPCR, GPR6 and GPR52. The direct and indirect pathways regulate motor behavior by smoothing locomotion and revoking movements [153, 193, 194].

Reactivation of D2R stimulates Gi/o-facilitated signalling in striatopallidal neurons, which inhibits the PKA (protein kinase A)/dopamine and cAMP-regulated phosphoprotein of 32 (DARPP-32) kDa channel, which can help with many dopamine-related behaviors [152]. Some other examples that can also regulate this pathway are Gs-coupled GPR52, GPR6, Gi-coupled GPR88, and adenosine A2a (Figure 4). These GPRs Gs-coupled are helpful to enrich NMDA (N-methyl-D-aspartate) receptor activity via cAMP/PKA. Dopamine shows a remarkably attenuated response to amphetamine in mice lacking βarr2. A protein-protein inter-face occurs in D2R, and DISC1 is found as an inducer of hyperactive activities in mice that needs to signal βarr2 to promote phosphorylation of AKT and consequent activation of GSK3β [153]. The mood stabilizer lithium hinders the triggering of GSK3β and collaboration in βarr2 and AKT [21]. The initial mode of action of antipsychotics in basal ganglia is antagonism of D2Rs and the first-line treatment for bipolar disorder and schizophrenia. As a result, a

---

**Table 2: Some GPCRs in the specific types of psychiatric disorders with the function, polymorphisms, and drugs targeting receptors.**

| Some GPCRs in psychiatric disorders | Normal function | Polymorphism/change in expression | Drugs targeting receptors |
|-------------------------------------|-----------------|-----------------------------------|---------------------------|
| 5HT1A receptors                     | Evidence that continuous antidepressant treatment results in desensitization of somatodendritic 5HT1A auto receptors in the dorsal raphe, and subsequent increase serotonergic transmission in the hippocampus supports the hypothesis that 5HT1A receptors play a role in mood disorders. | Five-HT1A receptor data from numerous research suggest that the 5HT1A receptor has a role in depression and treatment response. Lemonde and colleagues establish a link between the C-1019G 5HT1A promoter polymorphism and serious depression, suicide, and the effectiveness of the antidepressant flibanserin, a 5HT1A agonist. | Chronic lithium therapy in bipolar individuals normalizes abnormalities in 5HT1A receptor binding. |
| 5HT2A receptors                     | It has been demonstrated that antidepressants decrease the cortex’s 5HT2A receptor binding. | Five-HT2A receptor A-1438G, a promoter polymorphism in the 5HT2A gene, has been linked to serious depression. There have been numerous attempts to find a link between 5HT2A receptor polymorphisms and bipolar disorder, but these studies have not consistently shown any. | Studies examining the binding of the 5HT2A receptor after chronic lithium medication have yielded conflicting findings. Although studies in platelets have shown that lithium-induced increases in 5HT2A receptor binding capacity in bipolar individuals, the majority of research imply that lithium generates a decrease in 5HT2 receptor binding, with the strongest evidence in the hippocampus. |

---

**Figure 4: Model of GPCR-mediated NMDA receptor pathways in striatopallidal MSNs by phosphorylating it with cAMP.**
A genome-wide association study (GWAS) discovered the gene D2R within a schizophrenia-associated region to be effective for etiology and therapy [195], although antipsychotic medicines are not medically practicable for reducing cortical-related symptoms [196]. The classification of antipsychotics is typical and atypical. Haloperidol is a typical antipsychotic (first-generation antipsychotics) which principally has an inhibitory activity for D2Rs. Quetiapine, risperidone, and some others are examples of atypical antipsychotics (second-generation antipsychotics). They have an antagonistic activity for D2Rs, 5-HT2A (serotonin 2A receptor), and other several GPCRs, and they have fewer side effects than typical antipsychotics (Figure 5).

Different investigations have argued that a hyperdopaminergic state is the only reason for the development of schizophrenia. Additional evidence shows that the hyperdopaminergic state in the basal ganglia and the hyperdopaminergic state in the frontal cortex are also responsible (according to the dopamine hypothesis). Based on the reorganized dopamine hypothesis of psychosis [122], antipsychotics that block D2Rs were thought to simply reverse striatal hyperdopaminergic activity. So, the antipsychotic drug should simultaneously activate and inhibit dopamine signalling according to the brain region [197]. Antipsychotic medication might benefit from the discovery that D2Rs are capable of signaling not just through standard G protein pathways but also through noncanonical pathways that induce the creation of a signaling complex involving protein phosphatase2 (PP2A), GSK3β, 5AKT, and βarr2. Haloperidol initiates AKT phosphorylation in the brains of mice that could recompense for the defective activities of βarr2-GSK3β pathways in schizophrenia. D2R-βarr2 recruitment is blocked by all clinically effective antipsychotic medications. Antipsychotics which mainly target the pathway of D2R-βarr2 might have more therapeutically favourable effects but have fewer side effect like EPS [21, 178]. BRD5814, an arr2-biased D2R antagonist, improves dopamine-induced hyperlocomotion in mice while reducing motoric side effects [198]. Hence, the mechanisms of quetiapine and aripiprazole which are frequently used as antipsychotic drugs are discussed in the following sections.

8.1.1. Aripiprazole. Aripiprazole is an antipsychotic medication that was first approved for the treatment of a neuropsychiatric disorder called schizophrenia, which affects more than 1% population of the world. At D2R-Gi/o pathways, aripiprazole works as a partial agonist beneath high dopaminergic tone. They act like a biased D2R-Gi/o inhibitor [199]. Aripiprazole's agonist activity can completely block the D2R-arr2 translocation, which is triggered by dopamine. Aripiprazole also has antagonistic effects on other antipsychotics, such as hyperprolactinemia, metabolic disorder, extrapyramidal symptoms (EPS), weight gain, and sedation [20]. Aripiprazole does not affect the progression of cognitive impairment in schizophrenia patients. Parvalbumin, a calcium-binding protein, and mRNA transcription of the GABA-producing enzyme glutamic acid decarboxylase 67 (GAD67) are both downregulated in an autopsy of a patient with schizophrenia [200]. D2Rs are mediated in GABAergic FSIs in the prefrontal cortex (PFC), which control the activity possibilities of glutamatergic pyramidal neurons. Aripiprazole is only a partial agonist of D2R-βarr2 in the presence of GPCR kinase 2 (GRK2) in the cortical FSIs, although it has a limited effect on action potential firing [201]. Therefore, aripiprazole completely blocks the D2R-βarr2 pathway whereas stabilizing the D2R-Gi/o channel in the hyperdopaminergic striatum of the syndrome.

8.1.2. Quetiapine. Quetiapine, a typical antipsychotic agent, has been approved for diseases like schizophrenia and bipolar disorder [64]. Metabolic nor-quetiapine may mediate the antidepressant action of quetiapine, at least in part, via noradrenaline transporter inhibition [202]. Patients with bipolar illness have been found to benefit from...
Immediate-release (IR) and extended-release tablets (XR) of quetiapine, according to several studies [203]. Further investigation uncovers that a patient with schizophrenia has abnormal cytokine expression. Quetiapine shows unique anti-inflammatory and neuroprotective properties [107]. Quetiapine reduces the activation of astrocytes and microglia, as well as the synthesis and release of two cytokines, TNF-alpha and MCP-1, in mice (MCP-1). These results recommend that quetiapine may block injury by releasing cytokines and inhibiting glial cells' neuroinflammatory response. Quetiapine also shows activity by neuroprotective effect by increasing the delivery of brain-derived neuroprotective factor (BDNF) in contradiction of amyloid toxicity from cultured astrocytes [204]. Quetiapine shows unique regional and temporal transportation of epidermal growth factor receptor (EGFR) channel in mice, exhibiting EGFR-dependent striatal ERK1 activation and cortical ERK1 phosphorylation via aripiprazole is EGFR autonomous. The molecular actions of quetiapine are composite and could include influenced signaling [205].

9. Drug Discovery Areas for Psychiatric Disorders

Drug discovery for psychiatric disorders is slow and tedious [206]. There are several pathophysiological processes associated with genetic and environmental factors that may obstruct the drug development of such diseases [206, 207]. One of the major areas is target validation which contributes to the development of new drugs. Human brains are capable of storing a large amount of data, which can render our brains vulnerable in response to a stressful experience. For instance, PTSD is a psychiatric disease where patients can memorize horrible experiences like rape from their entire life. Trauma coupled with remembering past events activates neural plasticity in this situation [208]. Dysregulation of neuronal plasticity and brain atrophy is responsible for stress-related psychiatric disorders. Therefore, it has been suggested that the drug which possesses inhibitory effects on neuronal plasticity will be helpful in the management of this disorder [206]. Stress and depression are caused by glutamate hyperactivation, which is controlled by presynaptic proteins such as CaM kinase II. As a result, it may provide an opportunity to develop novel antidepressant medications [209]. Neuroimaging can provide an exact diagnosis of disease as well as the location of brain dysfunction. Developing new drugs will be feasible when the diagnosis is specific [206]. Additionally, imaging-based diagnosis has been an aid to the clinical management of psychiatric disorders.

10. Conclusions and Future Perspectives

Neurotransmitter imbalance leads to brain dysfunction in people with psychiatric illnesses. The GPCR may have a role in these conditions, as well as in psychiatric difficulties. As a result, the creation of new treatment options and pharmacological tactics is made easier with an in-depth knowledge of G protein-coupled receptor activities and signaling pathways. Several studies suggest that this dysfunction of ROS, glutathione, and oxidative stress is responsible for the alteration of brain function. The fact is that innovative drugs that simply imitate “traditional” treatments by altering neurotransmitter levels directly or indirectly may be of limited help to many patients with refractory illnesses. Altering synaptic activity will alter the system’s postsynaptic “throughput,” because such tactics presuppose that target receptors and downstream signal mediators are functionally intact. The direct targeting of postreceptor sites may be the sole strategy to enhance therapy for patients who are resistant to traditional medications, given the likely existence of GPCR abnormalities (and perhaps their signal transduction pathways). Research into the generation and deactivation of second messengers may lead to novel pharmacological medicines. Developing novel treatments that target second messenger systems may be possible since they are exceedingly varied at the molecular and cellular level, are connected to receptors in several ways, and are expressed in a wide variety of cell types and tissues. This, on the other hand, is more difficult than the development of receptor-targeted medications. These sites on the substrate serve as built-in targets for relative specificity of action since signal transduction pathways show varied properties based on their active state. Very recent achievements in new medicines for the long-term management of these serious mental illnesses are hugely encouraging. When it comes to the next phase of neuropsychopharmacology, it will be critical to apply the information obtained from advances in neuroscience and pharmacology in clinical settings. Moreover, a number of compounds and strategies have been discussed in this review for managing mental illness. Further investigations are required to develop standard treatment strategies with effective neuropotential effects. The present treatment approaches should be observed carefully to ensure their efficacy, or it should go for further development. However, more in-depth studies are required to identify more effective treatment approaches that aid in the improvement of current treatment methods and strategies. GPCR expression data from mice and humans can be used to model GPCR function in mental illnesses in a manner that is appropriate for animals. This data may also be used to find new therapeutic targets and anticipate on-target side effects.

Data Availability

All data are available within the text.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] H. Komatsu, M. Fukuchi, and Y. Habata, "Potential utility of biased GPCR signaling for treatment of psychiatric disorders," International Journal of Molecular Sciences, vol. 20, no. 13, p. 3207, 2019.

[2] CommonMind Consortium, PsychENCODE Consortium, iPSYCH-BROAD Working Group, "Shared molecular neuropathology across major psychiatric disorders parallels polygenic overlap," Science, vol. 359, no. 6376, pp. 693–697, 2018.
[3] N. Teroganova, L. Girshkin, C. M. Suter, and M. J. Green, “DNA methylation in peripheral tissue of schizophrenia and bipolar disorder: a systematic review,” BMC Genetics, vol. 17, no. 1, pp. 1–15, 2016.

[4] A. L. Hopkins, “Network pharmacology: the next paradigm in drug discovery,” Nature Chemical Biology, vol. 4, no. 11, pp. 682–690, 2008.

[5] P. Greengard, “The neurobiology of slow synaptic transmission,” Science, vol. 294, no. 5544, pp. 1024–1030, 2001.

[6] K. Sakuma, H. Komatsu, M. Maruyama, S. Imaiichi, Y. Habata, and M. Mori, “Temporal and spatial transcriptional fingerprints by anti-psychotic or prop-sychotic drugs in mouse brain,” PLoS One, vol. 10, no. 2, article e0118510, 2015.

[7] J. Gonzalez-Maeso and S. Sealfon, “Agonist-trafficking and hallucinogencs,” Current Medicinal Chemistry, vol. 16, no. 8, pp. 1017–1027, 2009.

[8] M. M. Rahman, S. A. Mim, M. R. Islam, N. Sultana, M. Ahmed, and A. K. Kanal, “Role of G-proteins and GPCR-mediated signalling in neuropathophysiology,” CNS & Neurological Disorders Drug Targets, vol. 21, 2022.

[9] M. M. Rahman, M. R. Islam, and T. Bin Emran, “Clinically important natural products for Alzheimer’s disease,” International Journal of Surgery, vol. 104, article 106807, 2022.

[10] Y.-X. Tao and P. M. Conn, “Chaperoning G protein-coupled receptors: from cell biology to therapeutics,” Endocrine Reviews, vol. 35, no. 4, pp. 602–647, 2014.

[11] D. M. Rosenbaum, S. G. F. Rasmussen, and B. K. Kobilka, “The structure and function of G-protein-coupled receptors,” Nature, vol. 459, no. 7245, article 4597245, pp. 356–363, 2009.

[12] A. Krishnan, H. B. Schiöth, and P. A. V. Anderson, “The role of G protein-coupled receptors in the early evolution of neurotransmission and the nervous system,” Journal of Experimental Biology, vol. 218, no. 4, pp. 562–574, 2015.

[13] S. M. Khan, J. Y. Sung, and T. E. Hébert, “The agonist and antagonist of G protein-coupled receptors leads to the identification of the postsynaptic density in bipolar disorder: A subgroup analysis and Montgomery-Asberg Depression Rating Scale and Hamilton Rating Scale for Depression item analyses of the Aripiprazole Depression Multicenter Efficacy study,” Psychiatry and Clinical Neurosciences, vol. 69, no. 1, pp. 34–42, 2015.

[19] S. F. Sonnenschein, K. M. Gill, and A. A. Grace, “State-dependent effects of the D2 partial agonist aripiprazole on dopamine activity in the MAM neurodevelopmental model of schizophrenia,” Neuropsychopharmacology, vol. 44, no. 3, pp. 572–580, 2018.

[20] G. F. Ma, N. Raivio, J. Sabrià, and J. Ortiz, “Agonist and antagonist effects of aripiprazole on D2-like receptors controlling rat brain dopamine synthesis depend on the dopaminergic tone,” International Journal of Neuropsychopharmacology, vol. 18, no. 4, pp. 1–9, 2015.

[24] A. L. Zhao, J. P. Zhao, Y. H. Zhang, Z. M. Xue, J. D. Chen, and X. G. Chen, “Dopamine d4 receptor gene exon III polymorphism and interindividual variation in response to clozapine,” International Journal of Neuroscience, vol. 115, no. 11, pp. 1539–1547, 2005.

[25] G. Luo, Y. Huang, B. Jia et al., “Quetiapine prevents Aβ25-35-induced cell death in cultured neuron by enhancing brain-derived neurotrophic factor release from astrocyte,” Neuroreport, vol. 29, no. 2, pp. 92–98, 2018.

[26] O. Dean, F. Giorlando, and M. Berk, “N-Acetylcysteine in Psychiatry: Current Therapeutic Evidence and Potential Mechanisms of Action,” Journal of Psychiatry and Neuroscience, vol. 36, no. 2, pp. 78–86, 2011.

[27] S. L. Ooi, R. Green, and S. C. Pak, “N-acetylcysteine for the treatment of psychiatric disorders: a review of current evidence,” BioMed Research International, vol. 2018, Article ID 2469486, 8 pages, 2018.

[28] R. Racz, B. V. Sweet, and P. Sohoni, “Oral acetylcysteine for neuropsychiatric disorders,” American Journal of Hospital Pharmacy, vol. 72, no. 11, pp. 923–929, 2015.

[29] L. A. Catapano and H. K. Manji, “G protein-coupled receptors in major psychiatric disorders,” Biochimica et Biophysica Acta (BBA) - Biomembranes, vol. 1768, no. 4, pp. 976–993, 2007.

[30] S. Shohag, S. Akhter, S. Islam et al., “Perspectives on the molecular mediators of oxidative stress and antioxidant strategies in the context of neuroprotection and neurolongevity: an extensive review,” Oxidative Medicine and Cellular Longevity, vol. 2022, Article ID 7743705, 20 pages, 2022.

[31] D. K. Vassilatis, J. G. Hohmann, H. Zeng et al., “The G protein-coupled receptor repertoires of human and mouse,” Proceedings of the National Academy of Sciences, vol. 100, no. 8, pp. 4903–4908, 2003.

[32] H. Komatsu, M. Maruyama, S. Yao et al., “Anatomical transcriptome of G protein-coupled receptors leads to the identification of a novel therapeutic candidate GPR52 for psychiatric disorders,” PLoS One, vol. 9, no. 2, article e90134, 2014.
[33] C. Gu, Y. Chen, C. F. Liu, Z. Zhu, and M. Wang, “Role of G protein-coupled receptors in microglial activation: implications in Parkinson’s disease,” *Frontiers in Aging Neuroscience*, vol. 13, 2021.

[34] S. Milutinović-Smiljanic, O. Šarenac, M. Lozić-Djurčić, D. Murphy, and N. Japundžić-Zigon, “Evidence for involvement of central vasopressin V1b and V2 receptors in stress-induced baroreflex desensitization,” *British Journal of Pharmacology*, vol. 169, no. 4, pp. 900–908, 2013.

[35] A. Sharma and L. Gupta, “Clonidine a wonder drug,” *Indian Journal of Anaesthesia and Analgesia*, vol. 6, no. 6, pp. 2057–2062, 2019.

[36] M. Elgeti, W. L. Hubbell, and J. Stein, “DEER analysis of GPCR conformational heterogeneity,” *Biomolecules*, vol. 11, no. 6, pp. 778, 2021.

[37] H. Aritake, T. Tamada, K. Murakami et al., “Effects of indacaterol on the LPS-evoked changes in fluid secretion rate and pH in swine tracheal membrane,” *Pflügers Archiv - European Journal of Physiology*, vol. 473, no. 6, pp. 883–896, 2021.

[38] D. Szarka, G. Elekes, O. Berczeli et al., “Alpha-adrenergic agonists stimulate fluid secretion in lacrimal gland ducts,” *Investigative Ophthalmology & Visual Science*, vol. 61, no. 14, pp. 3–3, 2020.

[39] C. Koval, H. Peyre, A. Amad et al., “Psychotic, mood, and anxiety disorders and venous thromboembolism: a systematic review and meta-analysis,” *Psychosomatic Medicine*, vol. 82, no. 9, pp. 838–849, 2020.

[40] A. M. Goodman, B. M. Langner, N. Jackson, C. Alex, and L. L. McMahon, “Heightened hippocampal β-adrenergic receptor function drives synaptic potentiation and supports learning and memory in the TgF344-AD rat model during prodromal Alzheimer’s disease,” *Journal of Neuroscience*, vol. 41, no. 26, pp. 5747–5761, 2021.

[41] M. K. Goyal, K. S. Yadav, and R. K. Solanki, “A study of thyroid profile in patients suffering from the first episode of mania: a cross-sectional study,” *Indian Journal of Psychiatry*, vol. 63, no. 4, pp. 395–399, 2021.

[42] C. P. Walsh, D. H. Borbély, and A. L. Marsland, “Glucocorticoid resistance and β2-adrenergic receptor signaling pathways promote peripheral pro-inflammatory conditions associated with chronic psychological stress: a systematic review across species,” *Neuroscience & Biobehavioral Reviews*, vol. 128, pp. 117–135, 2021.

[43] M. Falcinelli, P. H. Thaker, S. K. Lutgendorf, S. D. Conzen, R. L. Flaherty, and M. S. Flint, “The role of Psychologic stress in cancer initiation: clinical relevance and potential molecular mechanisms,” *Cancer Research*, vol. 81, no. 20, pp. 5131–5140, 2021.

[44] M. M. Rahman, S. Bibi, M. S. Rahaman et al., “Natural therapeuticst and nutraceuticals for lung diseases: traditional significance, phytochemistry, and pharmacology,” *Biomedicine & Pharmacotherapy*, vol. 150, article 113041, 2022.

[45] M. M. Rahman, M. R. Islam, F. Rahman et al., “Emerging promise of computational techniques in anti-cancer research: at a glance,” *Bioengineering*, vol. 9, no. 8, p. 335, 2022.

[46] J. J. Mann, D. Currier, J. A. Quirou, and H. K. Manji, “Neurobiology of severe mood and anxiety disorders,” in *Basic Neurochemistry*, pp. 1021–1036, Academic Press, 2012.

[47] I. Podolsky and S. Shrygol, “The behavioral study of the effects of atristamine on the serotonin, dopamine and norepinephrine neurotransmitter systems in mice,” *Farmacia*, vol. 67, no. 2, pp. 296–304, 2019.

[48] K. Lutfy and G. Shankar, “Emerging evidence for the role of pituitary adenylate cyclase-activating peptide in neuropsychiatric disorders,” *Progress in Molecular Biology and Translational Science*, vol. 167, pp. 143–157, 2019.

[49] M. Kusmider, A. Faron-Górecka, J. Solich, P. Fabian, and M. Dziedzicka-Wasylewska, “Time-course of changes in key catecholaminergic receptors and trophic systems in rat brain after antidepressant administration,” *Neurochemistry International*, vol. 141, article 104885, 2020.

[50] M. Ebrahimzadeh, *Effect of Multi-target Antidepressant Strategies on Monoamine Systems: ElectrophYSiological Studies in the Rat Brain, [Ph.D. thesis]*, University of Ottawa, 2021.

[51] N. B. Senese and M. M. Rasenick, “Antidepressants produce persistent Gas-associated signaling changes in lipid rafts after drug withdrawal,” *Molecular Pharmacology*, vol. 100, no. 2, pp. 96–111, 2021.

[52] M. G. Z. Ghali, U. P. Arborelius, and M. G. Yaşargil, “β-Adrenergic receptor structure and function: molecular insights guiding the development of novel therapeutic strategies to treat malignancy,” *Journal of Receptors and Signal Transduction*, vol. 40, no. 5, pp. 395–409, 2020.

[53] C. J. Harmer, R. S. Duman, and P. J. Cowen, “How do antidepressants work? New perspectives for refining future treatment approaches,” *The Lancet Psychiatry*, vol. 4, no. 5, pp. 409–418, 2017.

[54] N. B. Senese, M. M. Rasenick, and J. R. Traynor, “The role of G-proteins and G-protein regulating proteins in depressive disorders,” *Frontiers in Pharmacology*, vol. 9, p. 1289, 2018.

[55] E. Ciuffi, R. Karacay, A. Caglayan et al., “Neuroprotective effect of lithium in cold-induced traumatic brain injury in mice,” *Behavioural Brain Research*, vol. 392, article 112719, 2020.

[56] A. Tabecka-Lonczynska, J. Mytych, P. Solek et al., “IGF-1 as selected growth factor multi-response to antidepressant-like substances activity in C57BL/6J mouse testis model,” *Acta Histochemica*, vol. 123, no. 3, article 151685, 2021.

[57] C. M. Hurt, M. W. Sorensen, and T. Angelotti, “Common a2A and a2C adrenergic receptor polymorphisms do not affect plasma membrane trafficking,” *Naunyn-Schmiedebergs Archives of Pharmacology*, vol. 387, no. 6, pp. 569–579, 2014.

[58] X. Y. Peng, Y. Huang, X. L. Wang et al., “Adrenergic β2-receptor mediates itch hypersensitivity following heterotypic chronic stress in rats,” *Neuroreport*, vol. 26, no. 17, pp. 1003–1010, 2015.

[59] S. Veerasakul, K. Bandasak, P. Janthuang, S. Roytrakul, and S. Thanoi, “Proteomic analysis of frontal cortex proteins in a rat model of depression induced by dexamethasone,” *Naresuan Phayao Journal*, vol. 14, no. 1, pp. 3–15, 2021.

[60] H. Y. Yoon, J. Y. Park, J. Yee et al., “Effects of KCNMB2 gene polymorphisms on ritodrine therapy outcomes in women with preterm labor,” *Pharmacogenet Genomics*, vol. 15, no. 3, pp. 124–130, 2020.

[61] L. J. German-Ponciano, G. U. Rosas-Sánchez, S. I. Ortiz-Guerra, C. Soria-Fregoso, and J. F. Rodríguez-Landa, “Effects of chrysos on mRNA expression of 5-HT1A and 5-HT2A receptors in the raphe nuclei and hippocampus,” *Revista Brasileira de Farmacognosia*, vol. 31, no. 3, pp. 353–360, 2021.
[62] B. Etain, F. Bellivier, E. Olié et al., “Clinical predictors of recurrences in bipolar disorders type 1 and 2: a FACE-BD longitudinal study,” *Journal of Psychiatric Research*, vol. 134, pp. 129–137, 2021.

[63] H. H. Vilela-Costa, J. C. Maraschin, P. C. Casarotto et al., “Role of 5-HT1A and 5-HT2C receptors of the dorsal periaqueductal gray in the anxiety- and panic-modulating effects of antidepressants in rats,” *Behavioural Brain Research*, vol. 404, article 113159, 2021.

[64] D. S. Stenbaek, M. K. Madsen, B. Ozenne et al., “Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans,” *Journal of Psychopharmacology*, vol. 35, no. 4, pp. 459–468, 2021.

[65] J. Terock, A. Wehls, A. Teumer, J. Klinger-Kö nig, D. Janowitz, and H. J. Grabe, “Associations and interactions of the serotonin receptor genes 5-HT1A, 5-HT2A, and childhood trauma with alexithymia in two independent general-population samples,” *Psychiatry Research*, vol. 298, article 113783, 2021.

[66] D. Han, Z. Qiao, D. Qi et al., “Aims: Serotonin 1A receptor (5-HT1A) and vascular endothelial growth factor (VEGF) are widely expressed in the neurons of the hippocampus and have significant roles in the pathophysiological processes of major depressive disorders (MDDs). The present study was designed to examine 5-HT1A and VEGF gene polymorphisms and whether the gene–gene interaction of 5-HT1A and VEGF gene variants was associated with MDD,” *Frontiers Media SA*, 2020.

[67] K. Salaciak and K. Pytka, “Biased agonism in drug discovery: is there a future for biased 5-HT1A receptor agonists in the treatment of neuropsychiatric diseases?,” *Pharmacology & Therapeutics*, vol. 227, article 107872, 2021.

[68] I. M. Badamasi, M. S. Lye, N. Ibrahim, N. A. Abdul Razaq, K. H. Ling, and J. Stanslas, “Serotonergic receptor gene polymorphism and response to selective serotonin reuptake inhibitors in ethnic Malay patients with first episode of major depressive disorder,” *The Pharmacogenomics Journal*, vol. 21, no. 4, pp. 498–509, 2021.

[69] P. R. Albert, B. Le François, and F. Vahid-Ansari, “Genetic, epigenetic and posttranscriptional mechanisms for treatment of major depression: the 5-HT1A receptor gene as a paradigm,” *Journal of Psychiatry and Neuroscience*, vol. 44, no. 3, pp. 164–176, 2019.

[70] C. N. Yohn, M. M. Gergues, and B. A. Samuels, “The Role of 5-HT Receptors in Depression Tim Bliss,” *Molecular Brain*, vol. 10, no. 1, 2017.

[71] A. B. Ruzilawati, M. A. Islam, S. K. S. Muhamed, and I. Ahmad, “Smoking genes: a case–control study of dopamine transporter gene (SLC6A3) and dopamine receptor genes (DRD1, DRD2 and DRD3) polymorphisms and smoking behaviour in a Malay male cohort,” *Biomolecules*, vol. 10, no. 12, p. 1633, 2020.

[72] O. David, I. Barrera, N. Gould, S. Gal-Ben-Ari, and K. Rosenblum, “D1 dopamine receptor activation induces neuronal eEF2 pathway-dependent protein synthesis,” *Frontiers in Molecular Neuroscience*, vol. 13, p. 67, 2020.

[73] A. Pierzchlińska, J. Sławek, M. Mak, B. Gawrońska-Szkłarz, and M. Białecka, “Genetic polymorphisms in the renin-angiotensin system and cognitive decline in Parkinson’s disease,” *Molecular Biology Reports*, vol. 48, pp. 5541–5548, 2021.

[74] J. Holder, W. Wang, M. Lewis, and F. Wagner, *Dysfunction of D2 dopamine receptor expressing neurons underlies manic-like behaviors in mice modeling SHANK3 duplication disorder*, Research Square, 2021.

[75] B. J. Oters, R. K. Lenroot, G. Roberts et al., “Cortical mediation of relationships between dopamine receptor D2 and cognition is absent in youth at risk of bipolar disorder,” *Psychiatry Research: Neuroimaging*, vol. 309, article 111258, 2021.

[76] J. Kuhlman, I. Nykänen, M. Münty, and S. Harkikainen, “Association between frailty and dementia: a population-based study,” *Gerontology*, vol. 60, no. 1, pp. 16–21, 2014.

[77] V. V. Gafarov, E. A. Gromova, V. N. Maksimov, I. V. Gagulin, and A. V. Gafarova, “Association of personal anxiety with dopamine receptor D4 (DRD4), DAT genes polymorphism,” in *Anxiety Disorders-The New Achievements*, pp. 181–192, IntechOpen, 2020.

[78] M. M. Rahman, S. A. Mim, M. R. Islam et al., “Exploring the recent trends in management of dementia and frailty: focus on diagnosis and treatment,” *Current Medicinal Chemistry*, vol. 29, no. 32, pp. 5289–5314, 2022.

[79] O. Y. Alshogran, L. N. Al-Eitan, S. M. Altawalbeh, and H. A. Aman, “Association of DRD4 exon III and 5-HTTLPR VNTR genetic polymorphisms with psychiatric symptoms in hemodialysis patients,” *PLoS One*, vol. 16, no. 3, article e0249284, 2021.

[80] G. Drevin, M. Briet, S. Ghamrawi, F. Beloncle, and C. Abbarra, “Baclofen overdose following recreational use in adolescents and young adults: a case report and review of the literature,” *Forensic Science International*, vol. 316, article 110541, 2020.

[81] A. Khayachi, A. Ase, C. Liao et al., “Chronic lithium treatment alters the excitatory/ inhibitory balance of synaptic networks and reduces MGLURS–PKC signalling in mouse cortical neurons,” *Journal of Psychiatry and Neuroscience*, vol. 46, no. 3, pp. E402–E414, 2021.

[82] T. N. Wu, C. K. Chen, C. S. Lee et al., “Lithium and GADL1 regulate glycogen synthase kinase-3 activity to modulate KCTD12 expression,” *Scientific Reports*, vol. 9, no. 1, article 10255, 2019.

[83] I. D. Henter, L. T. Park, and C. A. Zarate, “Novel glutamatergic modulators for the treatment of mood disorders: current status,” *CNS Drugs*, vol. 35, pp. 527–543, 2021.

[84] S. Chakrapani, N. Eskander, L. A. De Los Santos, B. A. Omisore, and J. A. Mostafa, “Neuroplasticity and the biological role of brain derived neurtrophic factor in the pathophysiology and management of depression,” *Cureus*, vol. 12, no. 11, article e11396, 2020.

[85] M. Fornaro, I. Kardash, S. Novello et al., “Progress in bipolar disorder drug design toward the development of novel therapeutic targets: a clinician’s perspective,” *Expert Opinion on Drug Discovery*, vol. 13, no. 3, pp. 221–228, 2018.

[86] P. Mesdom, R. Colle, E. Lebigot et al., “Human dermal fibroblast: a promising cellular model to study biological mechanisms of major depression and antidepressant drug response,” *Current Neuropharmacology*, vol. 18, no. 4, pp. 301–318, 2020.

[87] S. Hoorisch-Clapach, “Mechanisms affecting brain remodeling in depression: do all roads lead to impaired fibrinolysis?,” *Molecular Psychiatry*, vol. 27, no. 1, pp. 525–533, 2021.

[88] M. Rezaei, M. M. S. Bagheri, and M. Ahmadi, “Clinical and demographic predictors of response to anodal tDCS treatment in major depression disorder (MDD),” *Journal of Psychiatric Research*, vol. 138, pp. 68–74, 2021.
[89] A. Wróbel, U. Doboszewska, E. Rechberger, P. Właż, and T. Rechberger, “SN003, a CRF1 receptor antagonist, attenuates depressive-like behavior and detrusor overactivity symptoms induced by 13-cis-retinoic acid in rats,” European Journal of Pharmacology, vol. 812, pp. 216–224, 2017.

[90] D. Vandaei and N. V. Gounko, “Corticotropin releasing factor-binding protein (CRF-BP) as a potential new therapeutic target in Alzheimer’s disease and stress disorders,” Translational Psychiatry, vol. 9, p. 272, 2019.

[91] J. M. Deussing, “Transcriptional and epigenetic regulation of the corticotropin-releasing hormone system and genetic associations with neuropsychiatric disorders,” Stress: Genetics, Epigenetics and Genomics, vol. 4, pp. 83–94, 2021.

[92] D. Hilger, M. Masureel, and B. K. Kobilka, and G. C. Sedvall, “Randomized controlled trials, meta-analysis for a systematic review and network meta-analysis of antidepressant drugs: current clinical practice and future directions,” Pharmacogenomics, vol. 13, no. 4, pp. 441–464, 2012.

[93] P. Habibzadeh, A. Nemati, H. Dastsooz et al., “Investigating the association between common DRD2/ANKK1 genetic polymorphisms and schizophrenia: a meta-analysis,” Journal of Genetics, vol. 100, p. 59, 2021.

[94] M. Di Bartolomeo, T. Stark, O. M. Maurel et al., “Crosstalk between the transcriptional regulation of dopamine D2 and cannabinoid CB1 receptors in schizophrenia: analyses in patients and in perinatal A9-tetrahydrocannabinol-exposed rats,” Pharmacological Research, vol. 119B, no. 1, article 105357, 2021.

[95] E. G. Jönsson, A. Sillén, M. Vares, B. Ekholm, L. Terenius, and G. C. Sedvall, “Dopamine D2 receptor gene Ser311Cys variant and schizophrenia: association study and meta-analysis,” American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, vol. 119B, no. 1, pp. 28–34, 2003.

[96] H. He, H. Wu, L. Yang et al., “Associations between dopamine D2 receptor gene polymorphisms and schizophrenia risk: a PRISMA compliant meta-analysis,” Neuropsychiatric Disease and Treatment, vol. 12, pp. 3129–3144, 2016.

[97] D. R. Herr, “Potential use of G protein-coupled receptor-blocking monoclonal antibodies as therapeutic agents for cancers,” International Review of Cell and Molecular Biology, vol. 297, pp. 45–81, 2012.

[98] G. Florez, P. Saiz, P. Garcia-Portilla et al., “Association between the Stin2 VNTR polymorphism of the serotonin transporter gene and treatment outcome in alcohol-dependent patients,” Alcohol & Alcoholism, vol. 43, no. 5, pp. 516–522, 2008.

[99] A. Lafaunet, M. Bernardo, S. Mas et al., “141C Ins/Del polymorphism of the dopamine D2 receptor gene is associated with schizophrenia in a Spanish population,” Psychiatric Genetics, vol. 18, no. 3, pp. 122–127, 2008.

[100] B. R. Lawford, R. M. Young, C. D. Swagell et al., “The C/C genotype of the C957T polymorphism of the dopamine D2 receptor (DRD2) is associated with schizophrenia,” Schizophrenia Research, vol. 73, no. 1, pp. 31–37, 2005.

[101] R. Kukreti, S. Tripathi, P. Bhatnagar et al., “Association of DRD2 gene variant with schizophrenia,” Neuroscience Letters, vol. 392, pp. 68–71, 2006.

[102] V. E. Golimbet, M. G. Aksenova, V. V. Nosikov, V. A. Orlova, and V. G. Kaleda, “Analysis of the linkage of the Taq1A and Taq1B loci of the dopamine D2 receptor gene with schizophrenia in patients and their siblings,” Neuroscience and Biobehavioral Physics, vol. 33, no. 3, pp. 223–225, 2003.

[103] T. Lenz, D. G. Robinson, K. Xu et al., “DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients,” American Journal of Psychiatry, vol. 163, no. 3, pp. 529–531, 2006.

[104] A. Leszczyńska-Rodziewicz, J. Hauser, M. Dmitrzak-Weglarz et al., “Lack of association between polymorphisms of dopamine receptors, type D2, and bipolar affective illness in a Polish population,” Medical Science Monitor, vol. 11, no. 6, pp. CR289–CR295, 2005.

[105] M. Schäfer, D. Rujescu, I. Giegling et al., “Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D2 receptor gene,” American Journal of Psychiatry, vol. 158, no. 5, pp. 802–804, 2001.

[106] S. Narasimhan and F. W. Lohoff, “Pharmacogenetics of antidepressant drugs: current clinical practice and future directions,” Pharmacogenomics, vol. 13, no. 4, pp. 441–464, 2012.

[107] E. Domínguez, M. I. Loza, F. Padin et al., “Extensive linkage disequilibrium mapping at HTRA2 and DRD3 for schizophrenia susceptibility genes in the Galician population,” Schizophrenia Research, vol. 90, pp. 123–129, 2007.

[108] E. J. Brandl, J. L. Kennedy, and D. J. Müller, “Pharmacogenetics of antipsychotics,” The Canadian Journal of Psychiatry, vol. 59, no. 2, pp. 76–88, 2014.

[109] N. Firouzabadi, A. Nazariat, and K. Zomorrodian, “DRD3 Ser9Gly polymorphism and its influence on risperidone response in autistic children,” Journal of Pharmacy & Pharmaceutical Sciences, vol. 20, pp. 445–452, 2017.

[110] M. U. Shad, “Genetic testing for antipsychotic pharmacotherapy: bench to bedside,” Behavioral Sciences, vol. 11, no. 7, pp. 97, 2021.

[111] T. M. Keck, W. S. John, P. W. Czoty, M. A. Nader, and A. H. Newman, “Identifying medication targets for psychostimulant addiction: unraveling the dopamine D3 receptor hypothesis,” Journal of Medicinal Chemistry, vol. 58, no. 14, pp. 5361–5380, 2015.

[112] X. Qi, J. Xuan, J. Xing, B. Wang, and J. Yao, “No association between dopamine D3 receptor gene Ser9Gly polymorphism (rs6280) and risk of schizophrenia: an updated meta-analysis,” Neuropsychiatric Disease and Treatment, vol. 13, pp. 2855–2865, 2017.

[113] F. L. Xu, X. Wu, J. J. Zhang, B. I. Wang, and J. Yao, “A meta-analysis of data associating DRD4 gene polymorphisms with schizophrenia,” Neuropsychiatric Disease and Treatment, vol. 14, pp. 153–164, 2018.

[114] T.-W. Lee, Y. W.-Y. Yu, C.-J. Hong, S.-J. Tsai, H.-C. Wu, and T.-J. Chen, “The influence of dopamine receptor D4 polymorphism on resting EEG in healthy young females,” The Open Neuroimaging Journal, vol. 6, pp. 19–25, 2012.

[115] P. Tybura, B. Trzeciowska-Drukala, and J. Samochowiec, “Pharmacogenetics of antipsychotic drugs in schizophrenia
treatment,” *Current Psychopharmacology*, vol. 1, no. 1, pp. 47–60, 2012.

[119] S. Numata, H. Umehara, T. Ohmori, and R. Hashimoto, “Clozapine pharmacogenetic studies in schizophrenia: efficacy and agranulocytosis,” *Frontiers in Pharmacology*, vol. 9, p. 1049, 2018.

[120] T. Bocek, J. Mackiewicz, M. Sobolczyk et al., “The role of G protein-coupled receptors (GPCRs) and calcium signaling in schizophrenia. Focus on GPCRs Activated by Neurotransmitters and Chemokines,” *Cells*, vol. 10, no. 5, p. 1228, 2021.

[121] G. Zhang and R. W. Stackman, “The role of serotonin 5-HT2A receptors in memory and cognition,” *Frontiers in Pharmacology*, vol. 6, p. 225, 2015.

[122] E. S. Lips, L. N. Cornelisse, R. F. Toonen et al., “Functional gene group analysis identifies synaptic gene groups as risk factor for schizophrenia,” *Molecular Psychiatry*, vol. 17, pp. 996–1006, 2012.

[123] C.-I. Lau, H.-C. Wang, J.-L. Hsu, and M.-E. Liu, “Does the dopamine hypothesis explain schizophrenia?,” *Reviews in the Neurosciences*, vol. 24, no. 4, pp. 389–400, 2013.

[124] J. Genius, I. Giegling, I. Benninghoff, and D. Rujescu, “Disturbed function of GABAergic interneurons in schizophrenia: relevance for medical treatment?,” *Current Pharmaceutical Biotechnology*, vol. 13, no. 8, pp. 1549–1556, 2012.

[125] Y. Zou, H. Zhang, X. Chen, W. Ji, L. Mao, and H. Lei, “Age-dependent effects of (+)-MK801 treatment on glutamate release and metabolism in the rat medial prefrontal cortex,” *Neurochemistry International*, vol. 129, article 104503, 2019.

[126] M. J. Fell, D. L. McKinzie, J. A. Monn, and K. A. Svensson, “Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia,” *Neuropharmacology*, vol. 62, no. 3, pp. 1473–1483, 2012.

[127] M. Kocot-Kepska, R. Zajaczkowska, J. Mika et al., “Topical treatments and their molecular/cellular mechanisms in patients with peripheral neuropathic pain—narrative review,” *Pharmaceutics*, vol. 13, p. 450, 2021.

[128] H. Machelska and M. Ö. Celik, “Opioid receptors in immune and glial cells—implications for pain control,” *Frontiers in Immunology*, vol. 11, p. 300, 2020.

[129] H. J. Carun, L. E. Kalynchuk, M. I. Loza, and J. M. Olivares, “Novel approaches to the neuropharmacology of mood disorders,” *Frontiers in Pharmacology*, vol. 10, p. 589, 2019.

[130] M. Rahman, F. Islam, M. Or-Rashid et al., “The gut microbiota (microbiome) in cardiovascular disease and its therapeutic regulation,” *Frontiers in Cellular and Infection Microbiology*, vol. 713, 2022.

[131] J. J. Liu, A. Hezhgia, S. R. Shaikh et al., “Regulation of monoamine transporters and receptors by lipid microdomains: implications for depression,” *Neuropsychopharmacology*, vol. 43, pp. 2165–2179, 2018.

[132] S. Kalkan, N. Hocaoglu, K. Oransay, M. Buyukdeligoz, and Y. Tunçok, “Adenosine-mediated cardiovascular toxicity in amitriptyline-poisoned rats,” *Drug and Chemical Toxicology*, vol. 35, no. 4, pp. 423–431, 2012.

[133] M. J. Nicu, D. F. Ionescu, D. C. Mathews, E. M. Richards, and C. A. Zarate, “Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part I: major depressive disorder,” *CNS Spectrums*, vol. 18, no. 5, pp. 231–241, 2013.

[134] Z. Zhang, T. Zhang, and K. Dong, “Icarin upregulates phosphorylated cyclic adenosine monophosphate response element binding protein levels in the hippocampus of the senescence-accelerated mouse,” *Neural Regeneration Research*, vol. 7, no. 12, pp. 885–890, 2012.

[135] E. M. Turner, L. L. Blazer, R. R. Neubig, and S. M. Husbands, “Small molecule inhibitors of regulators of G protein signaling (RGS) proteins,” *ACS Medicinal Chemistry Letters*, vol. 3, no. 2, pp. 146–150, 2012.

[136] P. Stockwell and P. Chidicai, *Scholarship @ Western Stability and Activity of Naturally Occurring RGS2 Variants*, Western Libraries, 2015.

[137] M. M. Rahman, M. R. M. R. Islam, S. Akash et al., “Recent advancements of nanoparticles application in cancer and neurodegenerative disorders: at a glance,” *Biomedicine & Pharmacotherapy*, vol. 153, article 113305, 2022.

[138] N. Jiang, R. Xue, F. Bu, X. Tong, J. Qiang, and R. Liu, “Decreased RGS6 expression is associated with poor prognosis in pancreatic cancer patients,” *International Journal of Clinical and Experimental Pathology*, vol. 7, no. 7, pp. 4120–4127, 2014.

[139] Y. Wang, Z. Geng, D. Jiang et al., “Characterizations and functions of regulator of G protein signaling (RGS) in fungi,” *Applied Microbiology and Biotechnology*, vol. 97, no. 18, pp. 7977–7987, 2013.

[140] E. Ross, “G protein-coupled receptors: multi-turnover GDP/GTP exchange catalysis on heterotrimeric G proteins,” *Cellular Logistics*, vol. 4, no. 2, article e29391, 2014.

[141] I. Masuho, S. Balaji, B. S. Muntean et al., “A global map of G protein signaling regulation by RGS proteins,” *Cell*, vol. 183, no. 2, pp. 503–521, 2020.

[142] K. J. Gerber, K. E. Squires, and J. R. Hepler, “Roles for regulator of G protein signaling proteins in synaptic signaling and plasticity,” *Molecular Pharmacology*, vol. 89, no. 2, pp. 273–286, 2016.

[143] K. E. Ahlers, B. Chakravarti, and R. A. Fisher, “RGS6 as a novel therapeutic target in CNS diseases and cancer,” *The AAPS Journal*, vol. 18, no. 3, pp. 560–572, 2016.

[144] S. Gaspari, I. Purushothaman, V. Cogliani et al., “Suppression of RGSz1 function optimizes the actions of opioid analgesics by mechanisms that involve the Wnt/β-catenin pathway,” *Proceedings of the National Academy of Sciences*, vol. 115, no. 9, pp. E2085–E2094, 2018.

[145] T. N. Lerner and A. C. Kreitzer, “RGS4 Is required for dopaminergic control of striatal LTD and susceptibility to parkinsonian motor deficits,” *Neuron*, vol. 73, no. 2, pp. 347–359, 2012.

[146] K. L. Egerod, M. S. Engeloft, M. L. Lund et al., “Transcriptional and functional characterization of the G protein-coupled receptor repertoire of gastric somatostatin cells,” *Endocrinology*, vol. 156, no. 11, pp. 3909–3923, 2015.

[147] T. Nagai, J. Yoshimoto, T. Kannon, K. Kuroda, and K. Kaibuchi, “Phosphorylation signals in striatal medium spiny neurons,” *Trends in Pharmacological Sciences*, vol. 37, no. 10, pp. 858–871, 2016.

[148] S. Petryszyn, J.-M. Beaulieu, A. Parent, and M. Parent, “Distribution and morphological characteristics of striatal interneurons expressing calretinin in mice: a comparison with human and nonhuman primates,” *Journal of Chemical Neuroanatomy*, vol. 59–60, pp. 51–61, 2014.
S. Grillner, B. Robertson, and M. Stephenson-Jones, “The evolutionary origin of the vertebrate basal ganglia and its role in action selection,” The Journal of Physiology, vol. 591, no. 22, pp. 5425–5431, 2013.

G. Gangarossa, J. Espallergues, P. Mailly et al., “Spatial distribution of D1R-and D2R-expressing medium-sized spiny neurons differs along the rostro-caudal axis of the mouse dorsal striatum,” Frontiers in Neural Circuits, vol. 7, p. 124, 2013.

Z.-X. He, T.-Y. Liu, Y.-Y. Yin, H.-F. Song, and X.-J. Zhu, “Substance P plays a critical role in synaptic transmission in striatal neurons,” Biochemical and Biophysical Research Communications, vol. 511, no. 2, pp. 369–373, 2019.

A. Wismüller and M. A. Vosoughi, “Classification of schizophrenia from functional MRI using large-scale extended Granger causality,” Medical Imaging 2021: Computer-Aided Diagnosis, vol. 11597, pp. 337–350, 2021.

G. Mocci, L. Jiménez-Sánchez, A. Adell, R. Cortés, and F. Artigas, “Expression of 5-HT2A receptors in prefrontal cortex pyramidal neurons projecting to nucleus accumbens. Potential relevance for atypical antipsychotic action,” Neuropharmacology, vol. 79, pp. 49–58, 2014.

T. Kikuchi, K. Maeda, M. Suzuki, T. Hirose, T. Futamura, and R. D. McQuade, “Discovery research and development history of the dopamine D2 receptor partial agonists, aripiprazole and brexpiprazole,” Neuropsychopharmacology Reports, vol. 41, no. 2, pp. 134–143, 2021.

A. Kruyer, J. Parrilla-Carrero, C. Powell et al., “Accumbens D2-MSN hyperactivity drives antipsychotic-induced behavioral supersensitivity,” Molecular Psychiatry, vol. 26, no. 11, pp. 6159–6169, 2021.

G. L. Dalton, S. B. Floresco, and A. G. Phillips, “Differential effects of d- and l-enantiomers of govadine on distinct forms of cognitive flexibility and a comparison with dopaminergic drugs,” Psychopharmacology, vol. 238, pp. 1069–1085, 2021.

B. M. Fritz, F. Yin, and B. K. Atwood, “Input-selective adenosine A1 receptor-mediated synaptic depression of excitatory transmission in dorsal striatum,” Scientific Reports, vol. 11, no. 6345, 2021.

A. Moreira-de-Sá, V. S. Lourenço, P. M. Canas, and R. A. Cunha, “Adenosine A2A receptors as biomarkers of brain diseases,” Frontiers in Neuroscience, vol. 15, article 702581, 2021.

S. Perez-Lloret and M. Merello, “Two new adenosine receptor antagonists for the treatment of Parkinson’s disease: istreadefylline versus toazenaden,” Expert Opinion on Pharmacotherapy, vol. 15, no. 8, pp. 1097–1107, 2014.

P. Jenner, A. Morì, S. D. Aradi, and R. A. Hauser, “Istradefylline—a first generation adenosine A2A antagonist for the treatment of Parkinson’s disease,” Expert Review of Neurotherapeutics, vol. 21, no. 3, pp. 317–333, 2021.

R. K. Bachtell, Cocaine Addiction and Adenosine A1 and A2A Receptors, Elsevier Inc., 2017.

G. Horváth, G. Ádám, G. Tuboly et al., “Caffeine–treat or trigger? Disparate behavioral and long-term dopaminergic changes in control and schizophrenia-like Wisket rats,” Physiology & Behavior, vol. 236, article 113410, 2021.

J. Miao, L. Liu, C. Yan et al., “Association between ADORA2A gene polymorphisms and schizophrenia in the North Chinese Han population,” Neuropsychiatric Disease and Treatment, vol. 15, pp. 2451–2458, 2019.

X. Wang and T. Li, “Role of adenosine kinase inhibitor in adenosine augmentation therapy for epilepsy: a potential novel drug for epilepsy,” Current Drug Targets, vol. 21, no. 3, pp. 252–257, 2020.

H. Komatsu, “Novel therapeutic GPCRs for psychiatric disorders,” International Journal of Molecular Sciences, vol. 16, no. 6, pp. 14109–14121, 2015.

S. Vandresen-Filho, P. C. Severino, L. C. Constantino et al., “N-methyl-D-aspartate preconditioning prevents quinolinic acid-induced deregulation of glutamate and calcium homeostasis in mice hippocampus,” Neurotoxicology Research, vol. 27, pp. 118–128, 2015.

L. Zhang, Y. Zhou, C. Liu et al., “Adenosine A2A receptor blockade improves neuroprosthetic learning by volitional control of population calcium signal in M1 cortical neurons,” Neuropharmacology, vol. 178, article 108250, 2020.

M. M. Rahman, M. R. Islam, M. T. Islam et al., “Stem cell transplantation therapy and neurological disorders: current status and future perspectives,” Biology (Basel), vol. 11, no. 1, p. 147, 2022.

M. M. Rahman, M. S. Rahaman, M. R. Islam et al., “Role of phenolic compounds in human disease: current knowledge and future prospects,” Molecules, vol. 27, no. 1, p. 233, 2021.

M. M. Rahman, M. T. Sarker, M. A. A. Tumpa et al., “Exploring the recent trends in perturbing the cellular signaling pathways in cancer by natural products,” Frontiers in Pharmacology, vol. 13, 2022.

M. M. Rahman, P. S. Dhar, F. Sumaia et al., “Exploring the plant-derived bioactive substances as antidiabetic agent: an extensive review,” Biomedicine & Pharmacotherapy, vol. 152, article 113217, 2022.

M. Haji, T. De Vita, C. Renassia et al., “Nonclassical ligand-independent regulation of Go protein by an orphan class C G-protein–coupled receptor,” Molecular Pharmacology, vol. 96, no. 2, pp. 233–246, 2019.

M. M. Rahman, F. Islam, S. Afsana Mim et al., “Multifunctional therapeutic approach of nanomedicines against inflammation in cancer and aging,” Journal of Nanomaterials, vol. 2022, Article ID 4217529, 19 pages, 2022.

M. M. Rahman, K. S. Ferdous, and M. Ahmed, “Emerging promise of nanoparticle-based treatment for Parkinson’s disease,” Biointerface Research in Applied Chemistry, vol. 10, pp. 7135–7151, 2020.

P. Atanes, T. Ashik, and S. J. Persaud, “Obesity-induced changes in human islet G protein–coupled receptor expression: implications for metabolic regulation,” Pharmacology & Therapeutics, vol. 228, article 107928, 2021.

A. G. E. Collins and M. J. Frank, “How much of reinforcement learning is working memory, not reinforcement learning? A behavioral, computational, and neurogenetic analysis,” European Journal of Neuroscience, vol. 35, no. 7, pp. 1024–1035, 2012.

A. S. Laun, S. H. Shrader, K. J. Brown, and Z.-H. Song, “GPR3, GPR6, and GPR12 as novel molecular targets: their biological functions and interaction with cannabidiol,” Acta Pharmacologica Sinica, vol. 40, pp. 300–308, 2019.

A. Nishi and T. Shuto, “Potential for targeting dopamine/DARPP-32 signaling in neuropsychiatric and neurodegenerative disorders,” Expert Opinion on Therapeutic Targets, vol. 21, no. 3, pp. 259–272, 2017.
[179] M. M. Rahman, K. S. Ferdous, M. Ahmed et al., “Hutchinson-Gilford progeria syndrome: an overview of the molecular mechanism, pathophysiology and therapeutic approach,” Current Gene Therapy, vol. 21, no. 3, pp. 216–229, 2021.

[180] M. Mominur Rahman, F. Islam, M. Saidur Rahman, N. A. Sultana, N. F. Fahim, and M. Ahmed, “Studies on the prevalence of HIV/AIDS in Bangladesh including other developing countries,” Advances in Traditional Medicine, vol. 21, no. 3, pp. 1–12, 2021.

[181] A. Mouri, H. Lee, T. Mamiya et al., “Hispidulin attenuates the social withdrawal in isolated disrupted-in-schizophrenia-1 mutant and chronic phenycyclidine-treated mice,” British Journal of Pharmacology, vol. 177, no. 14, pp. 3210–3224, 2020.

[182] G. Dallérac, X. Li, P. Lecouflet et al., “Dopaminergic neuro-modulation of prefrontal cortex activity requirements the NMDA receptor agonist d-serine,” Proceedings of the National Academy of Sciences, vol. 118, no. 23, article e2023750118, 2021.

[183] S. Hong and O. Hikosaka, “Diverse sources of reward value signals in the basal ganglia nuclei transmitted to the lateral habenula in the monkey,” Frontiers in Human Neuroscience, vol. 7, p. 778, 2013.

[184] D. Peleg-Raibstein, J. Hauser, L. H. L. Lopez, J. Feldon, P. A. Gargiulo, and B. K. Yee, “Baseline prepulse inhibition expression predicts the propensity of developing sensitization to the motor stimulant effects of amphetamine in C57BL/6 mice,” Psychopharmacology, vol. 225, no. 2, pp. 341–352, 2013.

[185] K. Nakazawa and K. Sapkota, “The origin of NMDA receptor hypofunction in schizophrenia,” Pharmacology & Therapeutics, vol. 205, article 107426, 2020.

[186] A. Hashi, B. F. O’Dowd, and S. R. George, “Dopamine D1-D2 receptor heteromer signaling pathway in the brain: emerging physiological relevance,” Molecular Brain, vol. 4, no. 1, pp. 1–6, 2011.

[187] S. Pehlivan, P. C. Aydin, M. A. Uysal et al., “Effect of monoamine oxidase B A644G variant on nicotine dependence and/ or schizophrenia risk,” Archives of Clinical Psychiatry (São Paulo), vol. 46, no. 1, 2019.

[188] C. Cepeda, K. P. S. Murphy, M. Parent, and M. S. Levine, “The role of dopamine in Huntington’s disease,” Progress in Brain Research, vol. 211, pp. 235–254, 2014.

[189] A. Mishra, S. Singh, and S. Shukla, “Physiological and functional basis of dopamine receptors and their role in neurogenesis: possible implication for Parkinson’s disease,” Journal of Experimental Neuroscience, vol. 12, 2018.

[190] D. J. Surmeier, M. Day, T. Gertler, S. Chan, and W. Shen, “D1 and D2 dopamine receptor modulation of gluta-matergic signaling in striatal medium spiny neurons,” Handbook of Behavioral Neuroscience, vol. 20, pp. 113–132, 2010.

[191] S. Ena, A. De Kerchove D’ExaErde, and S. N. Schiffmann, “Unraveling the differential functions and regulation of striatal neuron sub-populations in motor control, reward, and motivational processes,” Frontiers in Behavioral Neuroscience, vol. 5, p. 47, 2011.

[192] L. Li, L. Cheng, and Y. Wang, “Differential roles of two isoforms of dopamine D2 receptors in l-dopa-induced abnormal involuntary movements in mice,” Neuroreport, vol. 32, no. 7, pp. 555–561, 2021.

[193] A. S. Laun and Z.-H. Song, “GPR3 and GPR6, novel molecular targets for cannabidiol,” Biochemical and Biophysical Research Communications, vol. 490, no. 1, pp. 17–21, 2017.

[194] A. C. Bostan, R. P. Dum, and P. L. Strick, “Functional anatomy of basal ganglia circuits with the cerebral cortex and the cerebellum,” Current Concepts in Movement Disorder Management, vol. 33, pp. 50–61, 2018.

[195] J. M. Schrader, C. M. Irving, J. C. Octeau et al., “The differential actions of clozapine and other antipsychotic drugs on the translocation of dopamine D2 receptors to the cell surface,” Journal of Biological Chemistry, vol. 294, no. 14, pp. P5604–P5615, 2019.

[196] K. Kaneko, “Negative symptoms and cognitive impairments in schizophrenia: two key symptoms negatively influencing social functioning,” Yonago Acta Medica, vol. 61, no. 2, pp. 91–102, 2018.

[197] H. Zhu, D. Zhuang, Z. Lou et al., “Akt and its phosphorylation in nucleus accumbens mediate heroin-seeking behavior induced by cues in rats,” Addiction Biology, vol. 26, article e13013, 2021.

[198] M. Weißer, Q. Xu, J. P. Gale et al., “Functionally biased D2R antagonists: targeting the β-arrestin pathway to improve antipsychotic treatment,” ACS Chemical Biology, vol. 13, no. 4, pp. 1038–1047, 2018.

[199] H. Y. Chong, S. L. Teoh, D. B.-C. Wu, S. Kotirum, C.-F. Chiou, and N. Chaiyakanapruck, “Global economic burden of schizophrenia: a systematic review,” Neuropsychiatric Disease and Treatment, vol. 12, pp. 537–573, 2016.

[200] A. Imanishi, Y. Omori, H. Ishido et al., “Aripiprazole as a New Treatment for the Prolonged Nocturnal Sleep of Patient with Idiopathic Hypersomnia,” Psychiatry and Clinical Neurosciences, vol. 75, no. 10, pp. 320–322, 2021.

[201] G. D. Hofman, S. J. Dienel, H. H. Bazmi, Y. Zhang, K. Chen, and D. A. Lewis, “Altered gradients of glutamate and gamma-aminobutyric acid transcripts in the cortical visuospinal working memory network in schizophrenia,” Biological Psychiatry, vol. 83, no. 8, pp. 670–679, 2018.

[202] A. C. Altamura, D. Moliterno, S. Paletta et al., “Effect of quetiapine and norquetiapine on anxiety and depression in major psychoses using a pharmacokinetic approach: a prospective observational study,” Clinical Drug Investigation, vol. 32, no. 3, pp. 213–219, 2012.

[203] Y. Agid, G. Bussi, D. M. Diamond et al., “How can drug discovery for psychiatric disorders be improved?,” Nature Reviews Drug Discovery, vol. 6, no. 3, pp. 189–201, 2007.

[204] M. M. Rahman, S. A. Mim, M. A. A. Tumpa et al., “Exploring the management approaches of cytokines including viral infection and neuroinflammation for neurological disorders,” Cytokine, vol. 157, article 155962, 2022.

[205] M. E. Bauer and A. L. Teixeira, “Inflammation in psychiatric disorders: what comes first?,” Annals of the New York Academy of Sciences, vol. 1437, no. 1, pp. 57–67, 2019.

[206] R. Patel, R. N. Spreng, L. M. Shin, and T. A. Girard, “Neurocircuitry models of posttraumatic stress disorder and beyond: a meta-analysis of functional neuroimaging studies,” Neuroscience & Biobehavioral Reviews, vol. 36, pp. 2130–2142, 2012.

[207] A. Sebela, M. Kolenic, E. Farkova, T. Novak, and M. Goetz, “Decreased need for sleep as an endophenotype of bipolar disorder: an actigraphy study,” Chronobiology International, vol. 36, no. 9, pp. 1227–1239, 2019.
[208] K. Kamiya and O. Abe, “Imaging of posttraumatic stress disorder,” *Neuroimaging Clinics*, vol. 30, no. 1, pp. 115–123, 2020.

[209] Y. J. Cao, Q. Wang, X. X. Zheng, Y. Cheng, and Y. Zhang, “Involvement of SNARE complex in the hippocampus and prefrontal cortex of offspring with depression induced by prenatal stress,” *Journal of Affective Disorders*, vol. 235, pp. 374–383, 2018.